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ABSTRACT
Design and Evaluation of Peptide Lipid-Associated Nucleic Acids (PLANAs) for siRNA and
CRISPR/Cas9 Delivery and Protein Silencing
by Ryley Hall
Breast cancer affects 1 in 8 women in the United States. The American Cancer Society has
estimated that in 2020 about 276,480 new cases of invasive breast cancer will be diagnosed in
women. Cancer research has taken a turn in the last several decades to focus on new approaches
to combat the disease. This project focuses on two approaches, siRNA and CRISPR/Cas9 that can
have potential applications in cancer research
The first approach is a specific type of RNA interference (RNAi) that has been pursued
due to its therapeutic potential in cancer research. In short, siRNA delivery is a method of targeting
mRNA and reducing the protein expression in cancer cells. There are several advantages to siRNA.
First, siRNA does not alter the genetic information of the cell. Second, nucleus penetration is not
necessary. Third, siRNA is highly specific, which minimizes off-target effects. Lastly, due to the
lack of transfection and insertion into chromosomes, siRNA could be viewed as a “gene therapy
drug,” a characteristic more attractive for the pharmaceutical industry. Though, with these
advantages comes one major disadvantage. siRNA is notoriously difficult to deliver to the targeted
cells due to siRNA’s particular negatively-charged nature and instability. In order to overcome the
cellular delivery challenge faced by siRNA, we have designed peptide lipid-associated nucleic
acids (PLANAs) to enhance electrostatic interactions between siRNA and the cationic peptide and
hydrophobic interactions with the phospholipid bilayer of the cell.
The second approach is focused on utilizing CRISPR/Cas9 to target the gene that is causing
unwanted overexpression of proteins in cancer. The CRISPR/Cas9 plasmid contains guide RNA
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(gRNA) that is designed to target a specific gene of interest. The CRISPR/Cas9 plasmid can then
be employed to knockout the targeted gene. This method leads to permanent gene knockout,
altering the chromosomal DNA of the cell. Similarly to siRNA, the gRNA in the CRISPR/Cas9
plasmid is negatively-charged, creating difficulty in cellular delivery. Thus, PLANAs were also
utilized to enhance CRISPR/Cas9 delivery.
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Chapter 1. Introduction
1.1 Statement of the Problem
The overexpression of RPS6KA5 protein has been shown to be associated with breast
cancer1. This project utilized two approaches to decrease the overexpression of this protein. First,
siRNA was used to prevent the expression of the RPS6KA5 protein by preventing the translation
of mRNA to the protein. However, siRNA is negatively charged and hydrophilic, making it
challenging to deliver to the cell due to the aforementioned cell membrane properties. The second
method applied to decrease protein expression was CRISPR/Cas9. Similarly, the CRISPR/Cas9
plasmid contains negatively charged guide RNA, making cellular delivery challenging. Therefore,
an effective delivery method is needed to optimize siRNA and CRISPR/Cas9 delivery to make it
a viable cancer therapeutic agent.

1.2. The Beginning of RNAi
The RNAi approach was born with a breakthrough study by Andrew Fire and Craig Mello
that investigated gene inhibition by double-stranded RNA in C. elegans2. The RNAi mechanism
is a natural phenomenon that can degrade mRNA from a specific gene in order to prevent
translation. It was the potency and versatility of the RNAi approach in decreasing the expression
of genes that code for “undruggable” proteins that has enthused researchers. Previously
unfavorable targets, such as RAS and MYC oncogenes, in cancer have become now desirable
targets for researchers3. RNAi research has now spanned a wide variety of diseases, from viral
infections to a wide array of cancer targets and many areas in between.
The RNAi approach entertains three possible short duplex RNA molecules for gene
silencing: short interfering RNA (siRNA), short hairpin RNA (shRNA), and/or microRNA
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(miRNA). siRNA is a highly specific RNA molecule delivered to the cell with only one mRNA
target, whereas miRNA has multiple targets.4 shRNA holds those same properties as siRNA but is
processed within the cell to form siRNA4.
Utilizing these short duplex RNA molecules, two possible RNAi methodologies can be
employed: delivery of a nucleotide sequence by transfecting vectors or direct delivery of siRNA
or miRNA to the cytoplasm5. RNAi by means of the first method incorporates a nucleotide
sequence into the chromosome of the targeted cells resulting in a permanent expression of hairpin
loop structures5. The latter method, utilizing direct delivery of siRNA or miRNA to the cytoplasm
of targeted cells generates a temporary silencing effect of the targeted protein5.
Figure 1.1 illustrates the mechanism employed by RNAi. The presence of dsRNA in the
cytoplasm initiates the RNAi pathway. The dsRNA interacts with Dicer, an enzyme that cleaves
the dsRNA into a 22-nucleotide strand with 2 nucleotide overhands on the 3′ ends. The 22nucleotide strands then interact with the RNA-induced silencing complex (RISC), which separates
the strands, and the passenger strand is degraded. The guide strand stays in the RISC, establishing
the activated complex, which identifies and cleaves mRNA complementary to the guide strand.
Thus, the mRNA is effectively damaged, preventing translation to protein, silencing the gene
expression6.
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Figure 1.1. Illustration of the RNAi pathway.6
1.3. Challenges for siRNA Delivery
Though the discovery of RNAi as a method of gene therapy incited curiosity and
excitement among researchers, more than 20 years following the discovery, a faultless delivery
system is still yet to be uncovered. The relative instability and negative charge of siRNA are the
two main factors that pose challenges for intracellular delivery. Though siRNA is a doublestranded RNA molecule and more stable than if single-stranded, it is still susceptible to enzyme
degradation7. Its small size results in eliminations via glomerular filtration8. The inherent negative
charge of siRNA makes it hard to pass through the negative-charged cell membrane7. Naked
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siRNA, therefore, cannot be relied upon for successful gene silencing. Effective siRNA delivery
requires some type of carrier. Ability to mask the negative charge and stabilize siRNA to prevent
premature degradation are essential characteristics of a useful delivery system. The barriers that
must be overcome for effective siRNA delivery by nanoparticles is demonstrated in Figure 1.2.
The injected nanoparticle siRNA delivery system must circumvent filtration, phagocytosis, and
degradation while in the bloodstream, transport out of the bloodstream into the endothelial barrier,
disperse through the extracellular matrix, uptake into the cell, escape the endosome, and lastly
release the siRNA7.

Figure 1.2. Barriers faced in the in vivo delivery of siRNA.7
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Along with these challenges, the systematic administration of delivery agents to the
bloodstream is the only option for many tissues. In these cases, following the injection, siRNA
must pass through the circulatory system while avoiding filtration, uptake by phagocytes,
aggregation with serum proteins, and enzymatic degradation by endogenous nucleases 7.

1.4. Molecular Modifications
Molecular modifications to siRNA provide two essential functions in order to heighten the
likelihood that siRNA delivery leads to the desired gene silencing effect. The key purposes for
these modifications are to improve safety by decreasing the activation of endogenous immune
sensors responsible for detecting dsRNA9 and to advance the ability of dsRNA to repel degradation
by endogenous endonucleases and exonucleases10.
One of the known molecular modifications includes alterations to the 2′ sugar of the
nucleotide to reduce immune activation, increase in base pairing melting temperature, and improve
nuclease resistance11. Additional modifications can be made on the phosphate linkage and
individual bases of RNA molecules. The degree to which RNA molecules can be modified and
still retain potency depends mostly on the nature of the nucleic acid and its mechanism of action.
In the case of siRNAs, which rely on robust RISC, a significant amount of modifications can be
handled12.

1.5. siRNA Delivery Systems
Numerous non-viral siRNA delivery techniques have been established in efforts to
overcome the barriers mentioned. A mix of cationic and hydrophobic characteristics are relatively
common themes found among the various delivery systems reviewed. Cationic and ionizable
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lipids13, positively charged amino acids incorporated in peptide chains14, 15, and cationic polymers7
are some of the positively-charged and hydrophobic delivery techniques utilized in an attempt to
support cell internalization of siRNA. Some of the vehicles for siRNA delivery, including metal
nanoparticles, lipid-based materials, polymers,

cell-penetrating peptides

(CPPs), and

multicomponent nanoparticles are summarized here.

1.5.1. Metal Nanoparticles
Inorganic nanostructures have gained attention as a potential tool for siRNA delivery.
Amid the possibilities of metal nanoparticles, gold nanoparticles (AuNPs) have been attractive to
researchers due to their success in other areas16. In particular, gold and silver nanoparticles have
been of interest in gene therapy delivery systems due to relative simplicity of synthesis, malleable
size and shape, and surface modification possibilities 17.
AuNPs capped with peptides (LP-AuNPs) have been examined. A hexapeptide containing
alternative tryptophan and arginine amino acid residues LP-AuNPs was found to be proficient in
the delivery of fluorescence-labeled siRNA18. In this study, the sequence-selective AuNPs tested
that were free of surface modifications exhibited strong affinity to siRNA, increased uptake of
fluorescence labeled siRNA, and silenced the GAPGH gene in colon cancer cells.
Selenium nanoparticles (SeNPs) have displayed chemotherapeutic characteristics in
several studies19. They also embrace many features desirable for gene therapy: ideal size, elevated
gene loading capacity, heightened anticancer effect, and low toxicity 20. siRNA loaded selenium
nanoparticles were therefore, able to deliver siRNA into mice with hepatocellular carcinoma21. On
the surface of the SeNPs were polycationic polymers such as PEI as well as the hepatocellular
carcinoma tumor-targeting moiety hyaluronic acid (HA)21.

6

A Metal-organic framework (MOF) nanodelivery platform has been explored for the
targeted delivery of siRNA in vivo22. In this system, platelet cell membranes were coated with a
metal organic framework (MOF) for siRNA delivery. The MOF core was pH sensitive, enabling
endosomal disruption following cellular uptake and was able to deliver high loading yields. This
delivery method has accomplished high silencing in multiple targeted genes.

1.5.2. Lipid-based materials
Lipid nanoparticles as drug delivery systems have become progressively more attractive to
researchers. There are now over ten pharmaceutical drugs that have been formulated with lipid
nanoparticles and approved by the US Food and Drug Administration (FDA) 23. In late 2018, the
first ever FDA approved siRNA drug was brought to the market. Onpattro (patisiran) is the drug
that treats hereditary transthyretin-mediated amyloidosis via a lipid complex injection encasing
siRNA in lipid nanoparticles for effective delivery to targeted liver cells.
Positively-charged lipid delivery systems have become desirable to RNAi researchers.
While both cationic and ionizable lipids are utilized, the latter has become more desirable because
of the dependence of their charge dependence on the environmental pH, affording lower toxicity 24.
To maximize the delivery efficiency while keeping toxicity low, the pKa of the ionizable lipid
should aim to be low enough to stay unprotonated during circulation, but high enough to protonate
when reaching early or late endosomes6. For example, pH-sensitive cationic lipids comprising of
a protonable amine-based ethylenediamine head group, a hydrophobic group with two monounsaturated oleic acid tails, and a histidine-cysteine amino acid base linker have been evaluated13.
These pH-dependent lipids were able to silence luciferase in the HT29 colon cancer cell line even
more than the commercially available Lipofectamine RNAiMax13.
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PEG is a well-known shielding lipid included in many lipid-based delivery systems. The
presence of PEG serves many functions including reducing particle size, inhibiting aggregation
during storage, increasing circulation time, and reducing the uptake by off targets. However, PEG
groups also reduce uptake by targeted cells and reduce efficacy in vitro and in vivo25. In order to
limit the reduction in uptake by targeted cells, PEG-lipids with relatively short C14 acyl chains can
be applied to the delivery system23.
Lipid-like materials, also known as lipidoids are synthesized by the Michael addition of
alkyl-amines to alkyl-acrylates26,

27.

These synthesized materials contain tertiary amines,

permitting ionization, a key feature of effective siRNA delivery systems 28. Numerous lipidoids
have been analyzed for siRNA delivery. From the many tested, a few leads have been found 26.
Following analysis of merging lipidoids in binary combinations, it was found that the binary
combinations can be formulated together in a single vehicle to synergistically achieve high levels
of gene silencing in vitro on HeLa cells and in vivo in mice model studies28.

1.5.3. Polymers
siRNA delivery via polymers is another widely researched method. Cationic polymers
show promise because of their ability to concentrate nucleic acids, such as siRNA, into stable
nanoparticles for delivery7.
In this category are cyclodextrin polymer (CDP) nanoparticles. The polymers are made up
of polycationic oligomers that are synthesized through a stepwise polymerization between
diamine-bearing cyclodextrin monomers and dimethyl suberimidate producing oligomers with
amidine functional groups29. This type of polymer nanoparticle siRNA delivery system was the
first to enter clinical trials for cancer and had many benefits. The cationic polymer poses low
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toxicity, capability for stable and non-covalent steric stabilization by PEGylation of the CDP
siRNA nanoparticles, and the option for the addition of a ligand in order to improve in vivo uptake
and silencing efficiency30.
Lipopolymer/siRNA nanoparticles have been shown to slow the growth of chronic myeloid
leukemia cells both in vitro and in vivo31. An -linolenic acid substitution on low molecular weight
PEI was introduced to silence the BCR-ABL gene and protein, resulting in the reduction of CML
K562 cells in vitro and slowed the growth of localized tumors in a mouse model31.

1.5.4. Cell-Penetrating Peptides (CPPs)
Positively-charged amino acids in peptides have been used as an approach to siRNA
delivery because of their cell penetrating ability. These cationic amino acid residues form peptides
referred to as protein transduction domains (PTDs), Trojan peptides, membrane translocating
sequences (MTSs) model amphipathic peptides (MAPs), and most often CPPs14. The positive
charge and amphipathic nature of CPPs have been determined crucial for cellular internalization 32.
Taking into account the mentioned importance of positive charge and amphipathic features
for cellular internalization, amphipathic cyclic CPPs have been synthesized for siRNA delivery to
triple-negative breast cancer cells. Incorporation of alternative positively charged arginine (R) and
hydrophobic tryptophan residues into a CPP in [WR] 5 structure allowed efficient transportation of
siRNA to the cytoplasm15. This study also determined that attaching the hydrophobic tryptophan
residues to the cyclic peptide containing cationic arginine residues improved delivery of siRNA,
signifying that this structure enhanced hydrophobic interactions with the phospholipid bilayer of
the cell and electrostatic interactions between the positively charged residues and negatively
charged siRNA15.
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Stearylated CPPs cross-linked with disulfide bonds (SHRss) have been shown to efficiently
condense siRNA into stable nanoparticles that uptake into cells and allow rapid dissociation of
siRNA in the cytoplasm. The presence of siRNA in the cytoplasm was seen even after 24 h post
transfection33. Furthermore, the SHRss siRNA complexes were able to mirror the same high uptake
in vivo studies as well as show substantial gene silencing33.
-Aminoisobutryic acid (Aib) is a non-coded amino acid with a structure similar to alanine,
but with an -methyl group in place of an alanine -hydrogen. The conjugation of helical peptides
with Aib and 20 amino acid residues with cRGDfC at the C or N-terminus of the helical peptide
allows effective delivery of anti-luciferase siRNA into cells in order to induce the knockdown of
luciferase stably expressed in cells34. Similarly, 12-mer amphipathic peptides containing
disubstituted amino acids with hydrophobic substitutions were shown to form an

-helix

secondary structure suitable for siRNA delivery to human hepatoma cells 35.

1.5.5. Multicomponent Nanoparticles
Multicomponent lipid nanoparticles offer the ability to incorporate several components into
one delivery system. Some reoccurring components incorporated in multicomponent nanoparticles
are lipids, peptides, polymers, aptamers, and small drug molecules 36.
Resistance to current chemotherapies and the subsequent ongoing search for more effective
cancer treatments has prolonged cancer research. In the category of multicomponent nanoparticles
for siRNA delivery are aptamer-functionalized hybrid nanoparticles, which have been utilized for
the siRNA treatment of breast cancer as a delivery system37. These aptamer-conjugated
nanoparticles were employed to selectively deliver P-gp siRNA to metastatic breast cancer cells.
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It was found that the knockdown of P-gp was more significant when the particles were labeled
with the cancer cell-specific aptamer37.
The synergism between lipids and peptides in peptide-dendrimer/lipid/oligonucleotide
complexes have been shown to enhance transfection efficiency, while avoiding a high level of
toxicity38. In these ternary complexes, the improved efficacy in uptake and splice-switching
activity was found to be a product of the complexation of the dendrimer, rather than the identity
of the dendrimer used in the complex38.
Dynamic PolyConjugates (DPC) is a siRNA-polymer conjugate delivery system that
incorporates several working parts, each with intentional roles to improve siRNA delivery 6. In the
complexes, a hydrolysable disulfide bond linker attaches siRNA to a polymer that disrupts the cell
membrane and PEG side chains are incorporated to conceal the activity of the polymer. When the
complex is successfully uptaken into the acidic cell environment, PEG is released leaving the
polymer exposed, initiating endosomal release, reduction of the disulfide bond and producing free
siRNA6.
Stable nucleic acid-lipid particles (SNALPs) are amongst the multicomponent lipid
nanoparticles that have been explored for improved siRNA delivery. SNALPs are composed of a
cationic/ionizable lipid, fusogenic lipid, and a PEG lipid coating to form an aqueous shield around
the liposomes39. SNALPs form nanoparticles in the 100 nm range, making them ideal for cellular
internalization39. To date, SNALPs are seen as one of the most promising non-viral approaches to
in vivo siRNA delivery.
Modifications of the SNALP structure have been shown to improve delivery. For the
treatment of hepatic fibrosis, polypeptide pPB-SNALPs, with an ideal 110-130 nm size and neutral
zeta potential, showed increased uptake in vitro and in vivo compared to unmodified SNALPs40.
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The inclusion of the pPB cyclic oligopeptide, which was shown to have a strong binding affinity
with platelet-derived growth factor receptor

that is overexpressed on activated hepatic stellate

cells, in SNALPs allowed effective delivery to and treatment against hepatic fibrosis40. An in vivo
mouse model found that the IV administration of SNALPs alleviates Machado-Joseph disease of
the neurological phenotype41. The brain targeting SNALPs incorporated a cationic peptide with 9
arginine residues. The complexation of this peptide in a SNALPs framework presented high
encapsulation efficiency and protection of siRNA, while maintaining ideal particle size41. Another
study began with the ionizable cationic lipid 1,2-dilinoleyoxy-3-dimethylaminopropane
(DLinDMA) in the SNALP structure and used rational design to discover formulations with
improved function42. The leading lipid, (DLin-KC2-DMA) was formulated and characterized in
SNALP and exhibited in vivo siRNA activity at doses as low as 0.01 mg/kg in rodents and 0.1
mg/kg in nonhuman primates 42.

1.6. CRISPR/Cas9 History
CRISPR, short for clustered regularly interspaced short palindromic repeats, is an adaptive
immune system originally found in prokaryotes43. Though first reported in 1987, the now widely
known acronym was not proposed until 2002, following the discovery of numerous similar
structures in bacteria and archaea44. CRISPR associated (Cas) proteins are endonucleases that form
complementary base pairs with a target DNA sequence via a single guide RNA (sgRNA), which
signals for the cleavage of the DNA sequence at specific cites 45. Archaea and bacteria utilize this
mechanism as an immune defense against invasive nucleic acids from plasmids, phages, and other
mobile genetic elements46.
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Figure 1.3. CRISPR/Cas interference as an immune defense mechanism.47
The CRISPR/Cas system has been investigated in gene editing as the treatment for a
number of diseases. Compared to other methods of treating genetic diseases, gene editing has the
advantage of correcting the mutation causing the disease directly, effectively removing the need
for continued therapy. CRISPR/Cas9, therefore, holds a promising future in human gene therapy.
To date, a few of CRISPR/Cas9 achievements include correcting gene mutations that drive the
development of cancers48, selectively transducing and killing tumor cells via oncolytic viruses 49,
and replacing a specific genome sequence of human T cells with a modified sequence 50.
Furthermore, the first human clinical study of CRISPR/Cas9 was accomplished by injecting Cas9
engineered T cells into a patient with metastatic non-small cell lung cancer (NSCLC)51.
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The CRISPR/Cas systems are broken into two classes. Class 1 includes types I, III, and IV
contain a complex comprising multiple Cas proteins 1, whereas Class 2 comprises of types II, V,
and VI all of which hold a single Cas protein with multiple domains, giving rise to the latter types
simplicity and ease of use in gene engineering applications 45. Amid the different types of
complexes, the type II Cas9 is the most widely used in gene editing due to its high efficacy,
multifunctionality, and relative simplicity45. This system includes CRISPR spacers that lead the
system to the target. The Cas9 protein regulates the spacer acquisition as well as defense45.
Naturally occurring CRISPR systems perform three actions. First, adaptation integrates
foreign DNA protospacers into the CRISPR locus. The protospacers are selected based on the
protospacer adjacent motif (PAM)52. The next stage, expression, transcribes the CRISPR locus and
processes the pre-CRISPR RNA (pre-crRNA) into CRISPR RNA (crRNA)52. Last comes
interference, where genetic targets are detected and degraded by CRISPR RNA and Cas proteins.
crRNAs guide Cas9 to the PAM to cleave the complementary DNA. Specifically in type II, the
sgRNA-Cas9 complex binds to the target DNA, and Cas9 cuts both strands of DNA53.
Cas9 is composed of the RuvC and HNH nuclease domains. The RuvC domain is an
endonuclease named for an E. Coli protein involved in DNA repair. The HNH domain is an
endonuclease with critical histidine and asparagine amino acid residues. The HNH domain cuts
target DNA strands that are complementary to the sgRNA while the RuvC domain cuts other
noncomplementary target DNA strands54. The sgRNA comprises of CRISPR RNA (crRNA) and
the transactivating crRNA (tracrRNA), which together make the sgRNA 55.
There are three main strategies used for editing genes using the CRISPR/Cas9 system. The
first approach uses a CRISPR/Cas9 integrated plasmid that encodes the Cas9 protein and sgRNA
in one vector. This is the most widely used gene-editing approach due to the straightforward
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method that enables the delivery of both components in a single transfection56. Another strategy is
to deliver a coinjection of Cas9 mRNA and sgRNA57. The third strategy is to deliver a mixture of
Cas9 protein and sgRNA58.

1.7. The CRISPR/Cas9 Mechanism
Figure 3.1 presents the mechanism of CRISPR/Cas9. After the successful delivery of the
CRISPR/Cas9 system to the nucleus and localizing the target DNA, the Cas9 protein cleaves the
desired region to create a double-strand break (DSB). The DSB signals for cellular repair by one
of the cells endogenous DNA repair mechanisms. The nonhomologous end-joining (NHEJ) DNA
repair pathway is efficient but prone to errors due to the lack of a repair template. In this simple
mechanism, the ends of the DNA are ligated back together, frequently resulting in insertion or
deletion mutations that can disrupt the genomic locus reading frame. The second repair pathway
is the homology-directed repair (HDR) pathway, which applies a repair template. Here, the
template employs homology to the adjoining regions of strand by the DSB and incorporates an
extremely accurate modification of the genomic sequences to introduce specific nucleotide
changes into the target gene for gene knockout, tagging, mutations, knock-in, or promoter
studies54.
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Figure 1.4. CRISPR/Cas9 gene editing mechanism54.

1.8. Challenges for CRISPR/Cas9 Delivery
Notwithstanding the promise CRISPR/Cas9 holds in gene therapy, safe and successful
delivery of the system to targeted cells is a challenge yet to be solved. One of the challenges of
CRISPR/Cas9 delivery stems from the inherent negative charge of sgRNA, making the system
difficult to pass through the negatively-charged cell membrane. In response to this, many of the
following delivery methods integrate a cationic component to neutralize the negative charge from
the sgRNA. Moreover, in order to effectively edit the target gene, the CRISPR/Cas9 system needs
to be delivered to the desired site at an appropriate concentration 59. Thus, a suitable delivery
method is required.

16

1.8.1. Non-viral delivery systems
To overcome the challenges obstructing CRISPR/Cas9 from attaining a place on the
pharmaceutical market, several different non-viral delivery systems have been studied. These
delivery methods have made significant impacts in the race for CRISPR/Cas9 human gene therapy
attainment.
These delivery systems come with some advantages and disadvantages. First, synthetic
non-viral vectors are commonly well characterized and controlled, do not rely on a viral genome
for efficacy, are flexible to adjustments via chemical modification, tend to activate an immune
response less frequently compared to viral vectors, and are more easily upscaled for
pharmaceutical production than their biological counterparts 60. On the other hand, non-viral
delivery systems pose threats toward cell viability, have the possibility of problematic
biocompatibility, immunogenetic potential, and can pose issues with therapeutic cargo release60.
With that being said, the most common CRISPR/Cas9 non-viral delivery methods are reviewed
below.

1.8.2. Electroporation
Electroporation is a physical delivery tactic that momentarily restructures the cell
membrane creating a porous and non-selective surface via the application of a strong electric field.
This classic method is appealing to research for cancer immunogenic therapy as treatment of cells
with electric pulses can induce an immune response to solid tumors on its own. This response can
be supplemented by electroporation of plasmid DNA encoding therapeutic genes 61. Another area
of investigation that utilizes electroporation is gene editing in zygotes. For example, the diabetes
involved PDX-1 gene was targeted in pig zygotes. Cas9 protein with a variety of sgRNAs targeting
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the PDX-1 exon 1 was delivered to in vitro fertilized zygotes by the GEEP method (gene editing
by electroporation of Cas9 protein)62. The GEEP method led to the production of PDX-1 mutant
blastocysts. Another study has delivered CRISPR/Cas9 RNP using electroporation to human Bcells to stimulate the production of therapeutic proteins, achieving editing rates of up to 94%63.
Despite these positive results, there are some drawbacks to this method of delivery. The
efficiency of electroporation transfection is not consistent, but rather fairly diverse depending on
the type of tumor, the cell viability of electroporation is relatively low, and the method is not
appropriate for use in patients64, 65.

1.8.3. Microinjection
Injection of foreign molecules directly into a living cell at the microscopic level is a
common physical method of delivery of protein or DNA. In this process, the cell membrane is
punctured, and the protein or DNA is delivered directly to the target site of the cell66. This method
is best suited for in vitro and ex vivo settings, where efficacy can reach close to 100%67.
Microinjection is best suited for cells that multiply fast, such as zygotes, where injection of
CRISPR components to the nucleus often leads to which successful gene editing 60. A study was
conducted with the objective of validating the success of microinjection for cellular delivery of
CRISPR/Cas systems. In this study, microinjection was implemented in three different means:
injection of DNA into the pronucleus, injection of RNA into the pronucleus, and injection of RNA
into the cytoplasm68. The results indicated that injection of RNA into the cytoplasm was the most
efficient method of CRISPR/Cas9 delivery.
Some benefits of this method include the lack of limitations to the molecular weight of the
cargo that needs to be delivered, as well as the ability to control the amount of cargo and in turn
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limiting the off-target effects66. On the other hand, microinjection is a rather challenging and
technically difficult method, only offering a single microinjection per cell realistic66, as well as the
necessary labor of individual cell manipulation69.

1.8.4. Induced transduction by osmocytosis and propanebetaine (iTOP)
Induced transduction by osmocytosis and propanebetaine (iTOP) is a hyperosmolar buffer
made of a sodium chloride and propane betaine used to incite macro-pinocytosis for the cellular
uptake of proteins and other macromolecules. In the co-delivery of Cas9 protein and sgRNA into
human embryonic stem cells, 26% gene editing was observed after two administrations utilizing
iTOP70. Though iTOP has shown some observable gene editing efficiency, higher efficiency has
been seen in other methods such as electroporation, cationic lipids, and CPPs 58, 70, 71.

1.8.5. Mechanical cell deformation
Mechanical cell deformation enables the delivery of biomaterials by constructing shortterm membrane holes in the cell membrane. In the transport of Cas9 protein and sgRNA,
microfluidic membrane deformation has succeeded in many different cell types, while maintaining
high cell viability72. This method has led to greater than 90% knockout efficiency of EGF in the
MDA-MB-231 cell line as well as 70% knockout efficiency of EGF in the SU-DHL-1 (lymphoma)
cell line72.

1.8.6. Hydrodynamic injection
Hydrodynamic injection, a delivery system that works by injecting a solution intravenously
at tremendous volume and pressure, stimulates the transient generation of pores in the vasculature,
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enabling large macromolecules injected to have an increased chance of reaching the targeted
tissue65. This method used in the tail vein of mice has been able to deliver CRISPR/Cas9 plasmids
to the heart, lungs, liver, and kidney tissue73. One current drawback to hydrodynamic injection is
that it is limited to small animal models because of the necessary injection volume. Though, studies
are taking place in an effort to overcome this challenge for use in larger animal and ultimately
human use65.

1.8.7. Lipid nanoparticles
Lipid nanoparticles have become a widely studied delivery method for a variety of
treatments, including CRISPR/Cas9. Ionizable lipids are a common group of lipids to aid in
cellular internalization. In one study, pH-sensitive amino lipids (1-aminoethyl)iminobis[N(oleoylcysteinyl-1-aminoethyl)propionamide] (ECO) and isotypic ECO (iECO), were shown to
improve gene editing efficiency74. ECO and iECO have a protonable amino headgroup, two
cysteinyl residues, and two distant lipid tails, and were found to form nanoparticles in the 100200nm size range with the CRISPR/Cas9 plasmid. Compared to other lipids tested, ECO and iECO
displayed pH-sensitive hemolysis, increased expression of the CRISPR/Cas9 system and improved
gene editing efficiency, all while maintaining low cellular toxicity.
Another study utilizing ionizable lipids delivered Cas9 protein and sgRNA complexes,
resulting in 80% genome modification and improved specificity compared to DNA transfection58.
A multicomponent lipid nanoparticle, poly(ethylene glycol)-b-poly(lactic acid-co-glycolic acid)
(PEG-PLGA)-based cationic lipid assisted polymeric nanoparticles (CLANs), encapsulated a
CRISPR/Cas9 plasmid that targeted the BCR-ABL gene for therapy of chromic myeloid leukemia
(CML)75. In a further study, an ionizable lipid was combined with cholesterol, DSPC, and a
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PEGylated lipid to form nanoparticles for Cas9 mRNA and sgRNA delivery to rat livers. The
delivery vehicle aided in the transport of Cas9 mRNA and sgRNA targeting the transthyretin gene
and resulted in a decrease of more than 97% of serum transthyretin levels76.
Furthermore, commercial lipid-based reagents such as Lipofectamine , TurboFect , and
Stemfect

utilize cationic lipids to enhance the transfection efficiency of CRISPR/Cas9 among

other DNA and RNA delivery77.

1.8.8. Polymer nanoparticles
The flexible structure of polymers makes them a good candidate for the delivery of the
CRISPR/Cas9 system. Polymers have been studied as delivery agents for CRISPR/Cas9 due to
their flexibility, simplicity, and biocompatibility78.
A common cationic polymer for use in gene and drug delivery is poly(ethyleneimine)
(PEI)77. The branched PEI polymer has a high charge density, improving the packing of plasmid
DNA66. However, branched PEI is cytotoxic, which is the reason to complexing branched PEI with
less toxic linear PEI, for efficacious CRISPR/Cas9 delivery 66. Similarly, poly(amido amine)
(PAMAM) is a polymer with a high amount of primary amine groups on the boundary of the
polymer, forming strong complexes with DNA 77. For example, linear PAMAM polymer
dendrimers showed effective transfection of CRISPR/Cas9 plasmids to the human breast
adenocarcinoma cell line MCF-7 while sustaining a low cellular toxicity79. These linear polymer
dendrimers were designed, then redesigned in order to overcome packaging capacity as well as to
increase cell viability79.
The cationic polymer polyethyleneimine -cyclodextrin (PC) has proven to be an efficient
delivery method for small plasmid transfection. Recently, the polymer effectively delivered the
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larger Cas9 and sgRNA plasmid, resulting in the downregulation of the hemoglobin subunit beta
and rhomboid 5 homolog 1 19.1% and 7.0%, respectively80.
Addressing one of the hurdles to successful CRISPR/Cas9 delivery, opsonization, is the
polymer poly(ethylene glycol) (PEG). Conjugating the surface of nanoparticles with PEG has
shown to give the delivery system stealth properties to allow longer circulation in the blood after
intravenous injection59. An osteosarcoma (OS) cell-specific aptamer (LC09) was functionalized
with a PEG-PEI-cholesterol lipopolymer to encapsulate CRISPR/Cas9 plasmids targeting the
overexpressed vascular endothelial growth factor A (VEGFA) associated with OS 81. This polymerbased delivery system successfully edited the VEGFA gene, decreasing expression, while
presenting no signs of toxicity81.

1.8.9. Cell-penetrating peptides (CPPs)
CPPs are a class of cationic amphipathic peptides that are able to pass through the cell
membrane. CPPs have been found to use various mechanisms for cellular internalization. Energyindependent direct penetration and energy-dependent endocytosis are the two main routes of entry
that CPPs utilize32. Though both of these mechanisms have proven possible, endocytosis is the
more commonly accepted mechanism of internalization82.
The first report of CPPs for the delivery of CRISPR/Cas9 to mammalian cells utilized a
peptide with glycine, arginine, and leucine amino acid residues covalently conjugated to Cas9 and
linked to maleimide with sgRNA conjugated with a similar peptide without the maleimide 71. A
cysteine amino acid residue was bound to the C-terminus of the Cas9 protein in order to promote
SH-maleimide conjugation. The efficiencies of the delivery system and corresponding gene editing
were analyzed in a few different cell lines. Studies found that transfection efficiencies in
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HEK293T, HeLa, NCCIT, human dermal fibroblasts, and H9 human embryonic stem cells were
16%, 5.5%, 2.7%, 8.4%, and 2.3%, respectively. Though these percentages were fairly low, this
project was marked as one of the establishing non-viral vector delivery systems for CRISPR/Cas9
gene editing.

1.8.10. DNA nanostructure
Watson-Crick base pairing of small DNA fragments constructed the traditionally
complicated DNA nanostructures. A modernized method, rolling circle replication (RCR), has
permitted the assembly of DNA nanostructures with densely packed DNA83. This RCR method
has been employed to synthesize yarn-like DNA nanoparticles known as DNA nanoclews 84. The
DNA nanoclews were complexed with Cas9/sgRNA and delivered to human cells efficiently,
while maintaining low cytotoxicity. The greatest gene editing was observed when the DNA
nanoclew sequence was partially complementary to the sgRNA.

1.8.11. Gold nanoparticles
Gold nanoparticles (AuNPs) hold delivery functions in a range of capacities, including
CRISPR/Cas9 gene editing. For example, CRISPR/Cas9-ribonucleoprotein was efficiently
delivered using AuNPs, resulting in approximately 30% gene editing efficiency 85. CRISPRAuNPs have also been developed in conjugation with thiol-modified oligonucleotides, donor
DNA, and a cationic polymer poly(N-(N-(2-aminoethyl)-2-aminoethyl) aspartamide) [PAsp
(DET)]86. The design of this AuNP facilitated the delivery of CRISPR/Cas9 and donor DNA in
order to correct the mutated dystrophin gene in vivo.
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HIV-1-transactivator modified gold nanoparticles were found to enhance the delivery of
Cas9/sgRNA to cell nuclei87. The polyethylene glycol-lipid/GN/Cas9 protein/sgPlk1
plasmid/LGCP nanoparticle led to over 70% downregulation of Plk1 protein expression in the
A375 cell line. A related study analyzed condensed CPs on TAT peptide-modified AuNPs through
electrostatic (AuNPs/CP, ACP) interactions and coated lipids (DOTAP, DOPE, cholesterol,
PEG2000-DSPE) on the ACP to form lipid-encapsulated, AuNPs-condensed CP (LACP)88. This
investigation found that LACPs were able to enter tumor cells and release the CP into the
cytoplasm via laser-triggered thermo effects of the gold nanoparticles. This allowed the CP to enter
the nucleus by TAT assistance to knock out of the Plk-1 target gene. Encouraging results were
obtained both in vitro and in vivo.

1.9 Hypothesis and Rationale
1.9.1. siRNA Delivery Hypothesis and Rationale
The objective of this project was to utilize specific fatty acyl-peptide conjugates designed
to enhance siRNA delivery for mRNA silencing. The cyclic and linear peptides that were utilized
in this project contained five positively-charged arginine residues, a characteristic required to
interact with the negatively-charged siRNA. The positively-charged amino acids make also the
peptide a cell penetrating one. The fatty acid component will improve the interaction with the
hydrophobic residues in phospholipid of the cell membrane. Furthermore, the attraction between
the peptides and siRNA allows the peptide to encapsulate the siRNA, stabilizing siRNA, and
ensuring it does not degrade. This is a crucial feature as without the protection and stability that
the peptide provides, siRNA would not be able to penetrate the cell membrane and reach the
cytoplasm. A previous study found that palmitic acid (C16) and stearic acid (C18) conjugated
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peptides led to the best siRNA delivery89, and thus those peptides will be incorporated into
multicomponent nanoparticles for further review. We have termed these multicomponent
nanoparticles peptide lipid-associated nucleic acids (PLANAs), which are a novel delivery method
similar to the aforementioned SNALPs. The control formulation that does not incorporate any of
the selected peptides into this nanoparticle was named Lipid-Associated Nucleic Acid (LANA). It
is hypothesized that using fatty acyl-peptide conjugates incorporated in PLANAs structure will
enhance the cellular delivery of siRNA through appropriate electrostatic and hydrophobic
interactions with siRNA and phospholipid bilayer. There were three Specific Aims this project
focused on:

Specific Aim I. Design and synthesis of fatty acyl-peptide conjugates as siRNA delivery tools
Linear and cyclic difatty acyl-conjugated peptides (LP-C16, LP-C18, CP-C16, and CPC18) were synthesized by solid-phase peptide synthesis for use in the study of siRNA delivery89.
Cyclic peptides are more rigid and were predicted to provide higher stability versus the linear
counterparts toward proteolytic enzymes. After purification with HPLC, the structure of the
peptides was confirmed using MALDI-TOF mass spectrometry.
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LP-C18

LP-C16

Figure 1.5. Chemical structures of linear LP-C16 and CP-C18 peptides.

CP-C18

CP-C16

Figure 1.6. Chemical structures of cyclic CP-C16 and CP-C18 peptides.
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Specific Aim II. Encapsulation of siRNA by the fatty acyl-peptide conjugates and formation
of PLANAs
These peptides were used for siRNA encapsulation and incorporation into PLANAs
structure. Size and electric charge of siRNA carriers are important features to warrant efficient
delivery. To measure these values, dynamic light scattering (DLS) was used to ensure that the
assembly has the correct size, around 100 nm, and a positive charge around +10 mV. These
parameters were optimized by adjusting ratios of the components of PLANAs. Encapsulation
efficiency was determined by gel electrophoresis and dissociation rate confirmed by dialysis.

Specific Aim III. Determine the siRNA delivery and silencing effect using PLANAs and fatty
acyl-peptide complex
The cytotoxicity of the carrier was investigated using scrambled siRNA loaded PLANAs,
ensuring the safety of the system. The complex was used in cell-based assays to silence the overexpression of breast cancer-specific proteins in the breast cancer cell line MDA-MB-231. In this
work, we focused on silencing Ribosomal Protein S6 Kinase A5 (RPS6KA5) and proto-oncogene
tyrosine-protein kinase Src due to the implication of overexpression of both of these proteins seen
in breast cancer1,90. Lastly, the cellular internalization and cytoplasmic trafficking were confirmed
using flow cytometry and confocal microscopy.

1.9.2. CRISPR/Cas9 Delivery Hypothesis and Rationale
The purpose of this project was to effectively deliver CRISPR/Cas9 for gene editing using
a novel delivery system. The proposed delivery system utilized cyclic fatty acyl conjugated peptide
CP-C18 incorporated with lipids to form PLANAs. The rationale behind our design of PLANAs
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was detailed in the siRNA introduction. It is hypothesized that the use of PLANAs for
CRISPR/Cas9 transfection will improve delivery and in turn increase the efficiency of targeted
gene editing.

Specific Aim I. Design gRNA and transformation of CRISPR/Cas9 plasmid
Guide RNA (gRNA) was designed to target the RPS6KA5 gene that is overexpressed in
breast cancer. The CRISPR/Cas9 linear vector was ligated with the designed gRNA to form the
desired cyclic CRISPR/Csa9 gRNA plasmid. The plasmid was then transformed in competent E.
Coli cells and purified for transfection.

Specific Aim II. Encapsulation of CRISPR/Cas9 by LP-C18 and CP-C18 fatty acyl-peptide
conjugates incorporated into PLANAs
The CRISPR/Cas9 plasmid with the gRNA was encapsulated by PLANAs for efficient
transfection in the MDA-MB-231 cell line.

Specific Aim III. Determine the CRISPR/Cas9 delivery and gene-editing efficiency using
PLANAs
Following transfection, human CD4 nanobeads were used for cell sorting in order to
determine transfection efficiency. In order to confirm these efficiency rates, a genome editing
detection kit for PCR was used.
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1.10. Justification and Significance of the Study
As of today, no cyclic or linear peptides of this nature in combination with lipids to form
PLANAs have been reported for siRNA or CRISPR/Cas9 delivery. Though, we postulate that
positively-charged peptides and two hydrophobic fatty acid chains will increase interactions
between the two hydrophobic chains and the negatively-charged phosphate in the cellular
phospholipid bilayer. This aspect of the proposal that peptides contribute to the enhancement of
siRNA stability and delivery is our original idea.

1.11. Summary of Results
1.11.1. Chapter 2 Results
Chapter 2 focuses on the siRNA delivery portion of this project. Here, the synthesis of the
linear and cyclic fatty acyl-conjugated peptides is detailed. Furthermore, the design and
preparation of PLANAs is disclosed, and peptide and PLANA characterization studies are
revealed. Following characterization, the PLANA formulations were optimized in order to achieve
low cytotoxicity while maintaining maximum cellular uptake of siRNA. Results from cytotoxicity
and cellular uptake studies determined that PLANA formulations D and E succeeded in these areas.
From here, western blot silencing studies were conducted utilizing PLANA D for RPS6KA5 and
Src protein silencing in the MDA-MB-231 cell line. Silencing results concluded that PLANA D
acts as an effective siRNA delivery agent and led to enhanced protein silencing, comparable to
Lipofectamine™.
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1.11.2. Chapter 3 Results
Chapter 3 discusses the utilization of PLANAs for CRISPR/Cas9 delivery. Guide RNA
(gRNA) was designed to target and edit the RPS6KA5 gene. The designed sense and antisense
gRNA were annealed and ligated into a CRISPR nuclease vector and transformed in competent E.
coli cells. The CRISPR/Cas9 plasmids were then purified for transfection in MDA-MB-231 cells.
Following transfection, the cells were sorted via MojoSort Human CD4 nanobeads that are capable
of binding to the successfully transfected cells and the transfection efficiency was calculated.
Results determined that CP-C18 PLANA B, C, and D transfected 47.1%, 38.1%, and 49.0% of
cells, respectively. All PLANA formulations tested were more efficient in delivering
CRISPR/Cas9 than that of Liopfectamine™, which only transfected 22.3% of cells.
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Chapter 2
Design and Evaluation of PLANAs for siRNA Delivery and Protein Silencing

Abstract
RNAi is a biological process that utilizes small interfering RNA (siRNA) to prevent the
translation of mRNA to protein. This mechanism is beneficial in preventing the overexpression of
proteins in cancer. However, the cellular delivery of siRNA has proven to be challenging due to
its inherent negative charge and relative instability. Here, we designed a delivery system composed
of a linear or cyclic fatty acyl peptide conjugate (LP-C18 or CP-C18) and several lipids (DOTAP,
DOPE, cholesterol, and phosphatidylcholine) to form a multicomponent lipid nanoparticle, which
we have termed as peptide lipid-associated nucleic acids (PLANAs). Five formulations were
prepared (LANA and PLANAs A-D) using a mini extruder to form uniform nanoparticles around
100 nm in size. Our designed LANA and PLANAs A and B were assessed, and high cytotoxicity
and low cellular uptake results led to optimization via the removal of the cationic lipid DOTAP
and decrease of the overall cholesterol content to produce PLANAs C and D. The results revealed
that PLANAs C and D exhibited the best cellular uptake. LP-C18 PLANAs C and D afforded 82%
and 78% siRNA uptake, respectively and CP-C18 PLANAs C and D permitted 85% and 90%
siRNA uptake, respectively. From these results, PLANA D was chosen for silencing studies in
MDA-MB-231 triple-negative breast cancer cells, and both LP-C18 and CP-C18 PLANA D
formulations displayed effective protein silencing of both the RPS6KA5 and Src proteins.
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2.1 Introduction
2.1.1 Background
As mentioned in the introductory chapter, siRNA is notoriously difficult to deliver the cell.
In order to effectively deliver siRNA to the cell for protein silencing, an applicable siRNA carrier
must be applied in order to transport siRNA across the cell membrane.
Several methods of siRNA delivery have been studied. Metal nanoparticles such as AuNPs,
peptide conjugated AuNPs, and SeNPs have been shown to improve the delivery of siRNA due to
their ideal size, shape, and outer shell modification abilities 1-3. Polymers are another category of
siRNA delivery systems. In this group, cationic polymers are favored, due to their ability to interact
with negatively charged siRNA4. For example, cyclodextrin polymer (CDP) nanoparticles have
displayed low cytotoxicity, the ability for stabilization by PEGylation, as well as ligand addition
for improved siRNA uptake and protein silencing5.
Additionally, CPPs have exhibited effective siRNA delivery. Positively charge CPPs with
hydrophobic features to form an overall amphipathic natured cyclic [WR]5 peptide have permitted
delivery of siRNA to the cytoplasm of triple-negative breast cancer cells6. CPP delivery carriers
containing disulfide bonds have intrigued researchers due to their prompt dissociation and release
of siRNA once in the cytoplasm7. Lipid-based materials are another studied method of siRNA
delivery. PEG is one of the most commonly used lipids, as it is known to reduce particle size,
hinder aggregation, increase circulation time, and reduce off-target effects, but in turn, has a
lowered uptake by targeted cells8. Due to their ability to incorporate many different components,
multicomponent nanoparticles have gained attention. Stable nucleic acid-lipid particles (SNALPs)
are a multicomponent nanoparticle composed of a fusogenic lipid, cationic lipid, and PEG
shielding lipid that work together to enhance the ability of siRNA internalization 9. SNALPs are
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considered one of the leading non-viral approaches to in vivo delivery due to the ideal 100 nm size
and siRNA delivery capability9.
This study focused on linear and cyclic amphipathic fatty acyl-conjugated peptides in
conjugation with lipids for improved cellular delivery of siRNA. The delivery of siRNA via
peptide lipid-associated nucleic acids (PLANAs) was utilized for the silencing of the RPS6KA5
and Src proteins, both of which are known to be overexpressed in breast cancer cells.

2.1.2. Hypothesis
We hypothesized that fatty acyl-conjugated peptides incorporated into a multicomponent
lipid nanoparticle to form PLANAs will improve the cellular delivery of siRNA. The fatty acid
component of the peptide will enhance hydrophobic interactions with the phospholipid bilayer if
the cells and the cationic charge of the peptide will improve electrostatic interactions with siRNA.

2.1.3. Chemical Structures
Table 2.1. Peptide conjugate chemical structures.
Abbreviation
Chemical Structure
LP-C16
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Conjugated
Fatty Acid
Palmitic acid

Chemical
Formula
C76H148N24O11

LP-C18

Stearic acid

C80H156N24O11

CP-C16

Palmitic acid

C74H144N24O9

CP-C18

Stearic acid

C78H152N24O9

2.2. Experimental Procedures
2.2.1. Materials
XBridge BEH130 Prep C18 and XBridge BEH130 C18 columns from Waters Corporation
(Milford, MA, USA) were used for HPLC analysis. LC-2030C 3D and LC-20AP HPLC columns
used for the purification of the peptides were obtained from Shimadzu (Columbia, MD, USA).
High-resolution matrix-assisted laser desorption/ionization (MALDI) time-of-flight (MALDI-
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TOF, GT 0264) was manufactured by Bruker Inc. (Bremen, Germany). Mass spectra were
collected using a freshly prepared α-cyano-4-hydroxycinnamic acid in water (0.1% TFA) and
acetonitrile (0.1% TFA) in a 1:1 ratio (v/v) as the matrix that was mixed with the peptides before
the measurement. Tribute Automatic peptide synthesizer (Protein Technologies, Inc.) and all the
accompanying accessories and supplies were provided by Protein Technologies Inc. (Tucson, AZ,
USA). H-Arg(Pbf)-2-chlorotrityl resin (0.44 mmol/g), Fmoc-Arg(Pbf)-OH, Fmoc-Lys(Dde)-OH,
Dde-Lys(Boc)-OH, Dde-Lys(Fmoc)-OH, and Fmoc-Lys(Boc)-OH were purchased by AAPPTec
(Louisville, KY, USA). Palmitic
(DIPEA),

hydrazine

methylmorpholine,

acid, stearic acid, piperdine, N,N-diisopropylethylamine

monohydrate,
trifluoroacetic

anisole,
acid,

thioanisole,

acetonitrile,

dithiothreiitol
dichloromethane,

(DTT),

N-

α-cyano-4-

hydroxycinnamic acid, and trifluoroethanol (TFE) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). SYBR Green II, LipofectamineTM 2000, and Silencer® Negative Control siRNA
(Catalogue number AM4635) were obtained from Life Technologies (Grand Island, NY, USA).
1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP; chloride salt), cholesterol, phosphatidyl choline, and Avanti Mini Extruder
were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). All Western blot
requirements (including 10% Mini-PROTEAN® TGX Stain-FreeTM Protein Gels, MiniPROTEAN® Tetra Electrode Assembly, ClarityTM Western ECL Substrate, Trans-blot® TurboTM
Cassettes, Trans-Blot® TurboTM Mini PVDF Transfer Packs, Precision Plus Protein Western C
Standards, 10X Tris/Tricine/SDS, Bio-Safe Coomassie G-250 Stain, Coomassie Brilliant Blue R250 Destaining Solution, and 10x Tris/Glycine/SDS) were obtained from Bio-Rad (Hercules, CA,
USA). Cell Counting 8 (CCK8) KIT was purchased from Biotool (Houston, TX, USA; also known
as WST-8). VECTASHIELD VIBRANCE with DAPI (used to satin the cell nuclei) was obtained
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from Vector Laboratories (Burlingame, CA, USA). Biotech CE tubing (Cat. #131342; used as
dialysis bag) was purchased from Spectrum Labs (Rancho Dominguez, CA). Malvern Nano ZS
Zetasizer, disposable cuvettes, and disposable capillary cells were purchased from Malvern
Panalytical (Westborough, MA). All other reagents and consumables, including cell culture
requirements, and Texas Red (used to stain cell membrane) were provided by VWR (Radnor, PA,
USA).
AllStars negative control siRNA labeled with Alexa Fluor 488 (AF488; Catalogue number
1027292), and the siRNA targeting RPS6KA5 (Catalogue number SI02225433; Sense: 5′GCCAGUCAUUCGAGAUGAATT-3′; Antisense: 5′-UUCAUCUCGAAUGACUGGCTT-3′)
were purchased from Qiagen (Valencia, CA, USA). RPS6KA5 Human MSK1 (C27B2) rabbit
monoclonal Antibody (Catalogue number 3489S), anti-rabbit IgG, HRP-linked secondary
antibody (7074S), and human GAPDH (D4C6R) Mouse monoclonal antibody (Catalogue number
97166S) were provided by Cell signaling Inc. (Danvers, MA, USA). Anti-mouse polyclonal
secondary antibody (Goat Anti-Mouse IgG HRP-linked; Catalogue number HAF007) was
obtained from R&D Systems (Minneapolis, MN, USA).

2.2.2. Methods
2.2.2.1. Synthesis of peptides
2.2.2.1.1. Synthesis of cyclic peptides CP-C16 and CP-C18
Fmoc solid-phase peptide synthesis was utilized to synthesize the cyclic and linear difatty
acyl conjugated peptides, according to the previously reported procedure by us 10 except using
Fmoc-Lys(Dde)-OH for both lysine residues. In summary, H-Arg(Pbf)-2-Cl-Trt resin (0.40 mmol,
700 mg) was used as the solid support for the synthesis of cyclic peptide [R5K2]. Fmoc-Arg(Pbf)-
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OH and Fmoc-Lys(Dde)-OH were used as the building block amino acids (Scheme 2.1). The resin
was swelled in 10 mL of DMF in a reaction vessel under nitrogen for 30 min. and drained.
Coupling of the first amino acid was accomplished by adding 3 equivalents of Fmoc-Arg(Pbf)-OH
and 3 equivalents of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HBTU) in 7 mL of N,N-dimethylformamide (DMF) and 6 equivalents of N,Ndiisopropylethylamine (DIPEA) to the reaction vessel. The reaction was allowed for 1 h under
nitrogen. The mixture was then filtered and washed by 10 mL of DMF for 1 min. under nitrogen.
The solution was drained and filtered once more. The peptide was deprotected by piperidine in
DMF (20% v/v, 10 mL) under nitrogen for 15 min. The solution was filtered and deprotection was
repeated once more. The reaction was then washed for removal of any residual piperidine by 10mL
of DMF under nitrogen for 3 min.and then filtered. The washing was repeated once more. This
process was repeated using Fmoc-Arg(Pbf)-OH and Fmoc-Lys(Dde)-OH until the R5K2 peptide
chain was assembled on the resin. The cleavage from the 2-chlorotrityl resin was performed using
35 mL DCM, 10 mL trifluoroethanol, and 5 mL acetic acid for 1.5 h. The solution was then diluted
with hexane and evaporated four times. To cyclize the peptide, 3 equiv. of HOAt, 200 mL of
anhydrous DMF, 40 mL of anhydrous DCM, and 4 equivalents of DIC were added to the dry
peptide under nitrogen. The mixture was allowed to react for 24 h. Once cyclization was complete,
2% hydrazine in DMF was used to remove the Dde protecting groups. Palmitic acid or stearic acid
was then coupled to the unprotected lysine amino acid residues. This was accomplished by mixing
3 equivalents of the fatty acid with 2.5 equivalents of HBTU and 6 equivalents of DIPEA in DMF.
The fatty acid coupling was then repeated to ensure maximum coupling to the unprotected lysine
amino acid residues to yield CP-C16 and CP-C18. Final deprotection was carried out using 18 mL
TFA, 0.50 mL anisole, 0.50 mL thioanisole, and 50 mg DTT for 2.5 h.

51

CP-C16 MALDI-TOF (m/z): C74H144N24O9 calc: 1513.1548; found: 1516.3499 [M+3H]+. CPC18 MALDI-TOF (m/z): C78H152N24O9 calc: 1569.2174; found: 1571.2638 [M+2H]+.

2.2.2.1.2. Synthesis of linear peptides LP-C16 and LP-C18
H-Arg(Pbf)-2-Cl-Trt resin (0.40 mmol, 700 mg) was used as the solid support for the
synthesis of the linear peptide. Fmoc-Arg(Pbf)-OH and Fmoc-Lys(Dde)-OH were used as the
building block amino acids (Scheme 2.2.). The same procedure was used to assemble the linear
peptide chain on the resin as mentioned in cyclic synthesis. Once the peptide sequence was
assembled on the resin, the free N-terminus was capped by acetic anhydride (Ac2O) and HBTU
under nitrogen for 1 h. Both Dde protecting groups on the two lysine amino acid residues were
then removed by 2% hydrazine in DMF. 15 mL of the 2% hydrazine solution was added to the
peptide under nitrogen for 15 min. and filtered. This was repeated three more times. The peptide
was cleaved from the resin and was completely deprotected using the same procedure as in the
cyclic peptide synthesis. The fatty acid coupling was performed in the solution phase with either
stearic acid or palmitic acid, according to the previously reported procedure10 to afford LP-C16
and LP-C18.
A second synthesis method was developed for the linear LP-C18 (Scheme 2.3). The same
methodology was employed as the previous linear synthesis through Dde removal. Following Dde
removal, fatty acid conjugation was conducted in solid phase with 3 equivalents of stearic acid, 3
equivalents of HBTU, and 6 equivalents of DIPEA was performed on resin under nitrogen for 2 h.
Triple coupling was performed to ensure complete fatty acid coupling. The resin was then cleaved
using the previously stated procedure.
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Reverse-phase HPLC (RP-HPLC) was used to purify the crude R5K2 peptides. Gradient
elution was performed at a flow rate of 10 mL/min with the mobile phase composition ranging
from 95:5 (v/v) water/acetonitrile to 5:95 (v/v) water/acetonitrile throughout a 60-min run. The
mobile phase contained 0.1% TFA throughout the gradient. After fatty acid coupling, RP-HPLC
purification was repeated. Gradient elution was performed at a flow rate of 10 mL/min with the
mobile phase composition ranging from 95:5 methanol/isopropanol to 5:95 methanol/isopropanol
throughout a 60-min. run, as described previously10. The mobile phase contained a 0.1% TFA
throughout the gradient.
Matrix-Assisted Laser Desorption/Ionization Time of Flight (MALDI-TOF) mass
spectrometry was used to characterize the molecular weight using a matrix consisting of α-cyano4-hydroxycinnamic acid in acetonitrile (0.1% TFA) and water (0.1% TFA). 1 µL of peptide and 1
µL of the matrix was spotted on a MALDI-TOF plate and allowed to dry. The plate was then
inserted into the mass spectrometer and the mass was read using positive reflection mode.
LP-C16 MALDI-TOF (m/z): C76H148N24O11 calc: 1573.1759; found: 1575.1397 [M+2H]+. LPC18 MALDI-TOF (m/z): C80H156N24O11 calc: 1629.2385; found: 1631.4555 [M+2H]+.

2.2.2.2. PLANA design and preparation
PLANA were prepared with a different composition by mixing one of the four peptides
(CP-C16,

CP-C18,

LP-C16,

or

LP-C18),

with

DOTAP,

DOPE,

cholesterol,

and

phosphatidylcholine in one of the five PLANA formulations summarized in Table 1, with or
without siRNA. LANA A was formulated without peptide as a control to study the effect of
incorporation of the peptide into the composition. The peptide and siRNA were mixed in the
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aqueous portion, while stock solutions of lipids were added to the alcoholic portion, and the
aqueous:ethanol ratio was 3:1. Once the solutions were prepared, PLANAs were formed by
passing the mixture through an Avanti Mini Extruder (Alabaster, Alabama) with a 100 nm filter
50 times to obtain nanoparticles around 100 nm. To study the efficiency of this selected approach,
selected samples of PLANA A and PLANA C formulations were prepared with adding the peptide
to the ethanol solution (instead of aqueous phase).
Table 2.2. PLANA compositions (all components are specified as molar fractions).
Components (Molar fraction) LANA
Peptide
0
DOTAP
0.25
Cholesterol
0.25
Phosphatidylcholine
0.25
DOPE
0.25

PLANA A PLANA B PLANA C PLANA D
0.00625
0.0425
0.0425
0.0425
0.243
0
0
0
0.25
0.3195
0.1278
0.1278
0.25
0.3195
0.5102
0.2556
0.25
0.3195
0.3195
0.5102

The size and ʓ-potential of the nanoparticles were measured using a Malvern Nano ZS
Zetasizer (Westborough, MA). For size measurements, 70 µL of PLANAs was added to a
disposable cuvette (Cat. # ZEN0040) at 25 °C. For zeta potential measurements, 750 µL of
PLANAs was added to a disposable folded capillary cell (Cat. # DTS1070) at 25 °C and surface
charge determined at 40 V using Smoluchowski approximation.

2.2.2.3. Scanning Electron Microscope (SEM)
A sample for SEM microscopy was prepared by spotting peptide (5 μL of 0.5 mM solution
in H2O) solution or PLANA solution onto a glass coverslip, and the sample kept overnight to dry.
SEM analyses were conducted in a Zeiss NanoSEM using the directional backscatter (DBS)
electron detector.
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2.2.2.4. Transmission Electron Microscopy
TEM samples were prepared by spotting peptide (5 µL of 0.5 mM solution in H2O) solution
or PLANA onto a carbon-coated copper grid (300 mesh). The drop was allowed to stay on the
coverslip for 10 min. The excess solution was removed from the surface of the grid, and the sample
kept overnight to dry. The sample was examined at IMRI using a JEOL JEM-2100 transition
electron microscope. Images were recorded on a Gatan Oneview CCD camera at a magnification
of 25000x and 10000x.

2.2.2.5. Confirmation of peptide incorporation
Peptide incorporation in the PLANAs was measured using SDS-PAGE gel electrophoresis.
Different concentrations of free peptide were compared to PLANAs. 10%, 20%, and 100% of the
amount of free peptide in the PLANAs were run parallel to the PLANAs sample. 14 L of the
PLANAs, equivalent to 5 g of the peptide was run on a 16% polyacrylamide gel along with
different amounts of the free peptide (0.5 g, 1 g, and 5 g). 1X Tris/Tricine/SDS running buffer
(Cat. #1610744, Bio-Rad Hercules, California) was used in a Mini-PROTEAN Tetra
Electrophoresis Bio-Rad System. The system was run at 100 V and 35 mA until the dye reached
the bottom of the gel (approximately 90 min). After electrophoresis was performed, Bio-Safe
Coomassie G-250 Stain (Cat. #161-0786, Bio-Rad Hercules, California) was used to stain the gel
for 1 h and Coomassie Brilliant Blue R-250 Destaining Solution (Cat. #1610438) was used to destain the gel for 1 h, changing solution after 30 min. The bands were then visualized using a BioRad
Imager (Universal Hood III).
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2.2.2.6. Encapsulation efficiency
For determination of the encapsulation efficiency of the PLANA formulations, a previously
reported SYBR Green II dye exclusion assay was performed using a wide range of N/P ratios. This
method has been extensively used for DNA11, and by us for free siRNA quantification10, 12. siRNA
encapsulation was measured by adding 200 µL of SYBR Green Dye II (Cat. # S7564; 1:10,000
dilution) to 35 µL of the freshly prepared PLANAs sample in a 96 well BD FluoroBlok MW Insert
(Cat. # 137103). The fluorescence signal was quantified using a SpectraMax M5 V VIZ Plate
Reader at a λ excitation of 485 nm and a λ emission of 527 nm. Free siRNA in a wide range of
concentrations was used to create a standard curve for each set of experiments.

2.2.2.7. siRNA Release Study
Spectrofluorometry was performed to quantify siRNA release. A standard curve was
obtained by mixing siRNA, 1 M saline, and water to prepare different concentrations of siRNA
ranging from 30 nM to 0 nM. All samples were added to a 96 well BD FluoroBlok MW Insert. To
each sample, 200 µL of SYBR Green Dye II was added, and the fluorescence was read using a
SpectraMax M5 UV VIZ Plate Reader. 1 mL of PLANAs were added inside a 20 kDa MW cutoff
CE tubing dialysis bag (Cat. #131342) submerged in 30 mL DI water. 250 µL of the receiving
phase was sampled at pre-determined time points (30 min, 2 h, 4 h, 24 h, 48 h, and 72 h). Dialysis
bag samples were added to a 96 well BD FluoroBlok MW Insert. To each sample, 200 µL of SYBR
Green Dye II was immediately added, and the fluorescent signal was quantified using a
SpectraMax M5 UV VIZ Plate Reader as described in the previous section.
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2.2.2.8. Cell Line
Human breast cancer cell line MDA-MB-231 was purchased from American Type Culture
Collection (ATCC; Manassas, VA; Cat. #: HTB-26™). The cell line was cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% (v/v) FBS, 100 µg/mL streptomycin, and
100U/mL penicillin. The cells were maintained at 37 °C and 5% CO 2 and subcultured when 8090% confluent. Cells were discarded after 30 subcultures, and a new batch of cells was thawed
and cultured according to the same protocol. Human MRC-5 lung fibroblast cells (ATCC® CCL171™), H9C2 human myocardium cells (ATCC® CRL-1446™), PSC human epidermal
keratinocytes (HEKa) (ATCC® PCS-200-011™), and HepaRGTM human hepatocytes
(ThermoFisher Scientific; HPRGC10) were included in the cytotoxicity of the PLANAs, and were
grown according to the manufacturer’s guidelines.

2.2.2.9. Cytotoxicity
MDA-MB-231 cells were seeded in a 96-well plate. Once 70% confluency was reached,
the cells were treated in triplicate with one of the following groups: Normal saline (no treatment;
NT), PLANAs equivalent to 25, 50, 75, or 100 nM siRNA, or similar concentrations of PLANA
formulations without siRNA. PLANAs with LP-C18 and CP-C18 peptides were studied in this set
of experiments. Cells were exposed to different study groups and were incubated at 37 °C and 5%
CO2 for 48 h. A Cell Counting 8 (CCK8) KIT (Biotool; Houston, TX; also known as WST-8) was
used to evaluate the potential toxicity of the PLANA formulations on the viability of the cells.
After the incubation period, 10 uL of CCK solution (Cat. # B34304) was added to each well, and
plates were incubated at 37 °C for 1-2 h. The absorbance was then measured at 450 nm using a
SpectraMax M5 UV VIZ Plate Reader to determine cytotoxicity as a percentage of viable cells
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compared to the no treatment cells (after eliminating the signal from “Blank” cells (cell-less
medium with CCK-8 solution added)). All study groups were evaluated in triplicates.

2.2.2.10. Cellular Internalization
2.2.2.10.1. Flow cytometry
MDA-MB-231 cells were treated with one of the following study groups: Normal saline
(no

treatment;

NT),

AF488-siRNA

only,

AF488-siRNA/peptide

complex,

AF488-

siRNA/peptide/DOPE complex, one of the five different PLANA formulations, or
LipofectamineTM 2000 (as positive control) encapsulating AF488-labeled siRNA. Experiments
were performed with two peptides: LP-C18 and CP-C18. All treatment groups had a final siRNA
concentration of 36 nM. The cells were seeded in a 24-well plate (Cat. # 10062-896), and once
70% confluency was reached, study groups were added to the cell culture in triplicate wells.
LipofectamineTM was used according to the manufacturer’s guidelines. Briefly, Lipofectamine TM
and siRNA were diluted in FBS- and antibiotic-free OPTIMEM and were mixed. After 20 min.
incubation at ambient temperature, the cell culture medium was removed, and the siRNA
complexes were added to the wells in OPTIMEM. After 6 h of incubation at 37 °C, the complexes
were removed, and the cell culture medium was added to the wells. After 24 h incubation at 37 ºC
and 5% CO2, the media was removed, and the cells were detached using 0.05% trypsin. The cells
were fixed using 3.7% formaldehyde in 1X PBS and transferred to 3 mL FACS tubes. Each sample
was evaluated using a FACSVERSE flow cytometer (BD Biosciences; San Jose, CA). The
fluorescein isothiocyanate (FITC) channel was used to quantify cell-associated fluorescence.
Following each flow cytometry analysis, the percentage of cells positive for fluorescence signal,
and the mean fluorescence of the cell population was calculated using the calibration of the signal
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gated with NT cells in order to obtain an autofluorescence of approximately 1% of the population
in “no treatment” group.

2.2.2.10.2 Confocal Microscopy
MDA-MB-231 cells were treated with one of the following groups: AF488-siRNA only,
Lipofectamine™, LP-C18 PLANA D, or CP-C18 PLANA D. Sterilized cover slips were placed at
the bottom of wells in 6-well plates and were exposed to 10% FBS in DMEM and were incubated
for 30 min. at 37 °C to enhance the cell adherence to the cover slip surface. After incubation, the
FBS solution was removed, and cells were seeded on top of the cover slips. Once 70% confluency
was reached, the study groups were added. After 24 h incubation at 37 ºC and 5% CO2, the media
was removed, and cells were washed three times with 1 X PBS. Fixing solution (3.7%
formaldehyde in 1X PBS) was added for 10 min. The cells were rinsed 3 times in 1X PBS for 5
min. To stain the cell membrane, Texas Red Phalloidin solution (40 uL and 10 mg BSA in 10 mL
of 1X PBS) was added to the cells and incubated at room temperature for 1 h. The cells were then
washed 3 times with 1X PBS for 5 min. One drop of DAPI was added to a slide to stain the nucleus,
and the coverslips were placed face down without air bubbles and were stored overnight away
from light to dry. Once dry, a Nikon A1R high definition resonant scanning confocal microscope
and a NIS-Elements software (AR 4.30.02, 64bit) were used to image the cells.
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2.2.2.11. Protein Silencing
2.2.2.11.1 siRNA delivery
RPS6KA5 (also known as MSK1) and Src were selected as the model proteins for silencing
efficiency studies. MDA-MB-231 cells were seeded in 6-well plates as was described in previous
sections. After reaching 50% confluency, cells were treated with one of the following groups: no
treatment, siRNA targeting RPS6KA5 delivered by LipofectamineTM 2000, LP-C18 PLANA D,
or CP-C18 PLANA D. LipofectamineTM was used according to the manufacturer’s guidelines as
was explained in the previous section. The final siRNA concentration in the wells was 100 nM.
The cells were incubated at 37 ºC and 5% CO2 for 48 h.

2.2.2.11.2. Protein extraction
After 48 h of exposure to silencing siRNAs, media were removed, and the cells were
washed with HBSS. In order to detach the cells, 400 uL of 0.05% trypsin was added to each well,
and plates were incubated at 37 ºC for 2 min. The trypsin was deactivated with 2 mL DMEM
medium in each well. The cells for each treatment group were transferred to a 15 mL conical tube
and centrifuged at 600 rpm for 5 min. The supernatant was discarded and 1 mL 1X PBS was added
to the pellet. The pellet was resuspended by pipetting up and down, and the cells were transferred
to a 1.5 mL Eppendorf tube. The cells were centrifuged at 3400 rpm for 5 min. The supernatant
was discarded, and 35 uL of 1X Ripa buffer (containing protease and phosphatase inhibitors) was
added to the pellet and pipetted up and down. All tubes were kept on ice for 5 min, and then
sonicated for 2 min. The tubes were vortexed and kept on ice for 1 h, while vortexed every 15 min.
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The tubes were then centrifuged at the highest speed for 15 min at 4 ºC. The supernatant, containing
protein, was collected in a new 1.5 mL Eppendorf tube and the pellet was discarded.

2.2.2.11.3. Protein quantification
To quantify the total protein concentration, a portion of extracted protein was diluted 10
times in 1X PBS in a clean 1.5 mL Eppendorf tube. In a 96-well plate, 25 uL of each sample was
added in duplicates. Standards were prepared according to manufacturer’s instructions and 25 uL
of each standard concentration was added to the same 96-well plate in triplicate. 200 uL of reagents
A and B were added to each well, and the plate was placed on a shaker for 30 seconds. The plate
was then centrifuged at 1500 rpm for 2 min then incubated at 37 ºC for 30 min. The samples were
then analyzed using a spectrophotometer set at 562 nm.

2.2.2.11.4. Western blot
For each study group, 10 µg of total extracted protein (volume calculated based on the
protein quantification) was added to a 1.5 mL Eppendorf tube with enough 1X PBS to reach 25
µL final volume. To each sample, 25 µL dye was added, and tubes were vortexed and centrifuged
at the highest speed for 1 min. Tubes were then incubated at 95 ºC for 5 min. The samples were
centrifuged again and put on ice. The samples were loaded on a Mini-Protean TGX 10% gel and
run at 100 V and 75 mA for approximately 1 h. The protein was then transferred to a membrane
using a BioRad TransBlot Turbo Transfer System at 25 V and 1 A for 45 min. Once the proteins
were transferred, the membrane was washed in 1X TBS for 5 min. Then blocking was performed
by adding 1 g BSA in 20 mL TBST to the membrane for 1 h at room temperature. The primary
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antibody (1:1000) in 3% BSA in TBST was then added and left overnight at 4 ºC. The following
day, the membrane was washed with TBS-T six times (5 min each time) and was subsequently
incubated with corresponding secondary antibody in 3% BSA in TBST (1:1000) for 1 h at room
temperature. Then, the membrane was washed for 5 min 4 times in TBST. The blots were detected
by ECL Detect Kit using a ChemiDoc imager (Bio-Rad). The same procedure was followed for
visualizing GAPDH as the endogenous gene using corresponding antibodies to normalize the
intensity of the bands of the targeted protein.
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2.3. Results and Discussion
2.3.1. Chemistry
2.3.1.1. Solid-phase peptide synthesis of R5K2 fatty acyl conjugated peptides
Fmoc solid-phase peptide synthesis was utilized to synthesize linear and cyclic R5K2 fatty
acyl conjugates shown in Schemes 2.1-2.2. For all the peptides, H-Arg(Pbf)-2-Cl-Trt resin used as
the solid support, and Fmoc-Arg(Pbf)-OH and Fmoc-Lys(Dde)-OH amino acids were used as the
building blocks. Palmitic acid was conjugated to the lysine residues on the linear and cyclic R 5K2
peptide chains to form LP-C16 and CP-C16, respectively. Comparable conjugation was done using
stearic acid to form LP-C18 and CP-C18, respectively.
For the synthesis of the cyclic peptides, solution-phase fatty acid coupling was performed
effectively on both lysine residues (Scheme 2.1). The amino acids were assembled on the resin.
After cleavage from the resin, the side-chain protected linear peptide was cyclized. Both Dde
protecting groups were removed using 2% hydrazine in DMF under nitrogen. After deprotection
of lysine residues, fatty acyl conjugation was conducted to yield the products.
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Scheme 2.1. Synthesis of cyclic peptide-fatty acid conjugates CP-C16 and CP-C18.

Two linear synthesis methods were established. In the first method, shown in Scheme 2.2,
fatty acid conjugation was performed in solution phase after cleavage of R5K2 from the solid resin
support. The second method, presented in Scheme 2.2, illustrates fatty acid conjugation was done
on the solid phase before cleavage of R5K2 from the solid resin support. Both methods led to
successful fatty acid conjugation on both lysine residues.
The first method of linear synthesis (Scheme 2.2) performed fatty acid conjugation in the
solution phase following cleavage of R5K2 from the solid resin. This method proved challenging
as many side reactions occurred and the overall yield was low. Fatty acid coupling had to be
repeated many times in order to obtain full conjugation on both lysine residues. In the second
method (Scheme 2.2), fatty acid conjugation was performed in a solid phase reaction while the
peptide was on the resin. This method was simpler and more straightforward for fatty acid

64

NH2

conjugation. Triple coupling was performed to ensure full conjugation on both lysine residues, and
no side reactions were observed. In both linear schemes, the N-terminus of the peptide was capped
with an acetyl group to ensure selective fatty acid conjugation on the free amine groups of the
lysine residues.
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Scheme 2.2. Synthesis of fatty acid-linear peptide conjugates LP-16 and LP-18 (methods 1 and 2).
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2.3.1.2. Purification and mass spectrometry
Following synthesis and fatty acid conjugation, all fatty acid peptide conjugates were
purified according to the previously reported procedure10. Gradient elution was used over a 60minute run using isopropanol as solvent A and methanol as solvent B. The flow rate was set to 10
mL per min and elution of the peptide was detected using UV absorbance at 214 nm. Once the run
was completed, the collected fractions were analyzed using MALDI-TOF (Figures 2.1 and 2.2). A
sample of the purified peptide was mixed 1:1 with 𝛼-cyano-4-hydroxycinnamic acid in acetonitrile
(0.1% TFA) and water (0.1% TFA) to protonate the peptide for MALDI analysis. The following
mass spectra data were obtained for the purified peptides using m/z 900 to 3500 on positive
reflective mode.
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Figure 2.1. MALDI-TOF mass spectra of linear peptides.
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Figure 2.2. MALDI-TOF mass spectra of cyclic peptides.
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2.3.2. PLANA molar ratios
When designing the peptide lipid-associated nucleic acids (PLANAs), we started with a
molar fraction ratio of 25:25:25:25 for the four lipids (DOTAP, DOPE, cholesterol, and
phosphatidylcholine) (Table 1). This formulation (termed LANA) was used as a control, as it did
not contain peptide. For the next formulation, we replaced some of the cationic lipid DOTAP, with
the cationic peptide (PLANA A). Though, this formulation was found to have a higher zeta
potential than was desired, as well as high cellular toxicity and low uptake, leading us to
completely remove the cationic lipid. To compensate for the removal of DOTAP, the amount of
peptide was increased as well as the amount of the other lipids to generate PLANA B. Though this
formulation did show lower toxicity, PLANA B still was not yielding desired cellular uptake. In
an effort to increase cellular internalization, cholesterol was decreased13 and replaced with higher
amounts of phosphatidylcholine (PLANA C) or DOPE (PLANA D).
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2.3.3. Dynamic light scattering
Size and zeta potential of PLANAs were measured using dynamic light scattering. Both
size and zeta potential were measured at room temperature (25 C) immediately after preparing
PLANA formulations. The size of the PLANAs ranged from 88-201.3 nm (Figures 2.3 and 2.4).
The ideal lipid nanoparticle size for optimized in vivo cellular internalization is from 20200 nm. Nanoparticles in this range are large enough to escape renal filtration, but small enough
to avoid phagocytic clearance5. All PLANA formulations were around this desired size range
(Figures 2.3 and 2.4).
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Figure 2.3. Particle size of LP-C18 PLANAs.
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Figure 2.4. Particle size of CP-C18 PLANAs.

The zeta potential of the PLANAs ranged from 4.93-37.5 mV (Figures 2.5 and 2.6). The
data shown in Figures 2.5 and 2.6 illustrate that eliminating the cationic lipid (DOTAP) from the
PLANA formulation led to a lower zeta potential.
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Figure 2.6. Zeta potential of CP-C18 PLANAs.
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The zeta potential varied for the different PLANA formulations (Figures 2.5 and 2.6). The
formulations with DOTAP had a much higher zeta potential than the formulations without
DOTAP. The inclusion of the cationic lipid caused the charge of the PLANAs to be higher than
the desired range. When DOTAP was removed from the formulations, the zeta potential decreased.
For LP-C18 PLANAs B, C, and D, the zeta potential was in the ideal range of +2 to +10 mV. For
CP-C18 PLANAs B and C, the zeta potentials were a bit higher, +18.2 and +16.85, respectively,
but still much lower than the formulations with DOTAP. The differential zeta potential for CPC18 and LP-C18 is possibly due to their differential self-assembly pattern of the peptides (as
shown in electron microscopy), interactions with lipids and counterions, and availability of
positive-charge guanidine residues on the surface.
Size and zeta potential experiments were also conducted for formulations with the peptide
dissolved in the ethanol phase. Similar size and zeta potentials were observed for the formulations
with peptide in the ethanol phase compared to their aqueous counterparts.

2.3.4. Electron microscopy
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were
used to characterize the nanoparticle formation of PLANAs as well as peptide alone. For SEM
analysis, LP-C18 and CP-C18 peptides were spotted after 24 h incubation at room temperature to
allow peptide self-assembly. LP-C18 PLANAs were formulated and immediately spotted and
allowed to dry before analysis. LP-C18 and LP-C18 PLANAs both show nanoparticle formation
around 50-100 nm (Figures 2.7a and 2.7b), respectively. CP-C18 was found to form bigger
nanoparticles, around 500-1000 nm (Figure 2.7c). The larger observed nanoparticles suggest that
some aggregation may have occurred during the sample preparation. The 24 h incubation period
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for self-assembly appear to be too long. The amphipathic nature of the peptides in this study drives
self-assembly. Thus, reducing the self-assembly time may lead to smaller less aggregated
nanoparticles. Additionally, CP-C18 formed vesicle-like nanoparticles, with a cavity in the middle
(Figure 2.7c). The structure of the cyclic peptides resembles a phospholipid, containing a
hydrophilic cyclic head group and two hydrophobic fatty acid tail. This structural assembly
promotes the formation of nanoparticles with a bilayer.
For TEM analysis, CP-C18 PLANAs were spotted on a carbon-coated copper grid
immediately after formulation preparation. For analysis of peptide alone, CP-C18 was allowed to
self-assemble at room temperature for 24 h and then spotted on a carbon-coated copper grid.
Similar to the images obtained from SEM (Figure 2.7d), TEM showed that CP-C18 self-assembled
to form vesicle-like nanoparticles around 500 nm (Figure 2.7d). CP-C18 PLANAs were found to
form nanoparticles around 200 nm with some aggregated larger particles (Figure 2.7e).
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Figure 2.7. Electron microscopy images of peptides and PLANAs: (a). SEM image of LP-C18
peptide alone after 24 h self-assembly at room temperature; (b). SEM image of LP-C18 PLANA
A immediately following formulation preparation; (c). SEM image of CP-C18 peptide alone after
24 h self-assembly at room temperature; (d). TEM image of CP-C18 peptide alone after 24 h selfassembly at room temperature; (e). TEM image of CP-C18 PLANA A immediately following
formulation preparation.

2.3.5. Peptide incorporation studies using SDS PAGE Gel Electrophoresis
In order to verify that peptide is effectively incorporated into the PLANA nanoparticles,
the free peptide was compared to the PLANA A formulation using SDS-PAGE gel electrophoresis.
Due to the amphiphilic nature of the peptides in this study, they are able to dissolve in both aqueous
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and organic solvents. Because of this, studies were conducted in order to establish any differences
in peptide incorporation that might be presented in the different solvent systems. Since the lipid
nanoparticles contain both an aqueous phase and ethanol phase, we included peptide dissolved in
both of these phases in our analysis.
Using SDS-PAGE gel electrophoresis, the PLANA A formulations were compared to 10%,
20%, and 100% of the free peptide (Figures 2.8-2.12). Free peptide is much smaller than the
PLANAs. Thus, PLANAs would run more slowly on the gel compared to peptide alone. Shown
on the gel images, the PLANAs with LP-C16, LP-C18, or CP-C18 peptides dissolved in the
aqueous phase revealed no band corresponding to free peptide (Figures 2.8-2.10). From this, it can
be concluded that the peptide in the aqueous phase is fully incorporated with the lipids in the
PLANAs. When the experiment was repeated with peptide in the ethanol phase, a faint band was
observed for both LP-C18 and CP-C18 PLANAs (Figures 2.11 and 2.12). Therefore, it can be
established that the peptide incorporates more efficiently when incorporated in the aqueous phase
of the PLANAs.
When the solution of lipids in the PLANAs was introduced with the aqueous peptide, the
configuration of nanoparticles integrated better with the peptide. When the lipids were mixed with
peptide in the ethanol phase, formation of nanoparticles was not initiated until the addition of
water. The former method was found to better incorporate peptide into the multi-component lipid
nanoparticles. These results led us to use the peptide in the aqueous phase for better peptide
incorporation in PLANAs. It is also to note that in some of the images, oligomerization was
detected in some of the free peptide bands (Figures 2.8, 2.10-2.12). Oligomerization is a common
phenomenon among peptides and proteins14. Particularly, the amphipathic nature of the peptides
in this study contribute to self-assembly.
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Figure 2.8. SDS-PAGE gel electrophoresis image of LP-C16 PLANA A– peptide in the aqueous
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Figure 2.9. SDS PAGE gel electrophoresis image of LP-C18 PLANA A–peptide in the aqueous
phase.
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Figure 2.10. SDS-PAGE gel electrophoresis image of CP-C18 PLANA A–peptide in the aqueous
phase.
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Figure 2.11. SDS-PAGE gel electrophoresis image of LP-C18 PLANA A–peptide in the ethanol
phase.
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Figure 2.12. SDS-PAGE gel electrophoresis image of CP-C18 PLANA A–peptide in the ethanol
phase.

2.3.6. siRNA encapsulation by PLANAs
To ensure that PLANAs can effectively encapsulate siRNA, and in turn act as an efficient
delivery system, encapsulation studies were performed. The negative charge of siRNA should be
neutralized by the cationic peptide, and DOTAP in some formulations, for feasible cellular
delivery. As well, encapsulation of siRNA will protect siRNA from premature degradation before
reaching the targeted cells.
siRNA encapsulation in different PLANA formulations was measured immediately after
preparing the PLANAs using a SYBR Green Dye II exclusion assay. All PLANA formulations
were tested, as well as a few formulations with the peptide dissolved in the ethanol phase (LP-C18
PLANA A and CP-C18 PLANA C). The fluorescence data shows that the formulations with
peptide in the aqueous phase encapsulate siRNA more efficiently than PLANA formulations with
peptide in the ethanol phase (Figures 2.13 and 2.14). All CP-C18 PLANA formulations with
peptide in the aqueous phase showed significant siRNA encapsulation at time 0. LP-C18 PLANAs
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A, B, and D showed notable siRNA encapsulation. However, LP-C18 PLANA C had less siRNA
encapsulation at time 0 than the other formulations. The increase amount of phosphatidylcholine
in LP-C18 PLANA C seemed to disrupt the encapsulation of siRNA. However, this disruption was
not found in CP-C18 PLANA C, as free siRNA was just under 5%. The cyclic CP-C18 peptide
has a more rigid structure than its linear counterpart, which seems to have improved siRNA
encapsulation in this formulation. As for the peptides dissolved in the ethanol phase, much lower
siRNA encapsulation was observed. These results are consistent with peptide incorporation, as the
PLANAs with peptide dissolved in ethanol showed lower peptide incorporation. If the peptide is
not efficiently incorporated into the lipid nanoparticles, then siRNA will be less effectively
encapsulated, due to the electrostatic interactions that occur between siRNA and peptide.
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Figure 2.13. siRNA encapsulation at time 0 via LP-C18 PLANAs.
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Figure 2.14. siRNA encapsulation at time 0 via CP-C18 PLANAs.

2.3.7. siRNA release studies
In order to achieve improved cellular delivery of siRNA, the PLANAs delivery system
needs to achieve a sustained release profile of siRNA. Dialysis was used to measure siRNA release
rate from PLANAs, and siRNA release was quantified using spectrofluorometry. The PLANA
formulation being tested was added inside a 20 kDa MW cutoff dialysis bag and submerged in 30
mL DI water. Samples were taken from the receiving phase at 30 min, 2 h, 4 h, 24 h, 48 h, and 72
h. SYBR Green Dye II added to each sample and the absorbance was read.
Compared to siRNA alone, all of the PLANA formulations released siRNA in a more
sustained manner (Figure 2.15). siRNA released from the dialysis bag into the receiving phase
more slowly when incorporated into PLANAs than on its own. The sustained release of siRNA
from PLANAs is ideal because it allows siRNA to reach and internalize into targeted cells before
being released. However, the delivery vehicle should not be so stable as to not release siRNA for
silencing once internalized into the targeted cells. After 72 h the release of siRNA from PLANAs
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varied from 18 to 53%. This investigation was conducted in a controlled dialysis experiment, with
no other cellular interference. With this in mind, we expect in in vitro and in vivo settings, the
sustained release would be mirrored, but with a slightly quicker release.
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Figure 2.15. siRNA release profile of PLANAs.

2.3.8. Dynamic light scattering of PLANAs before and after dialysis
The same method was used for size and zeta potential measurements of PLANAs before
and after dialysis experiments as mentioned above. Several formulations were tested: LP-C18
PLANA A, CP-C18 PLANA A, CP-18 PLANA B, LP-C18 PLANA C, LCP-C18 PLANA C, and
LP-C18 PLANA D. The size of the PLANA formulations before and after the 72 h dialysis
experiment are summarized in Figure 2.16. Most formulations that were tested decreased in size
after the 72 h dialysis experiment. CP-C18 PLANA B did not follow this trend, but rather increased
in size, most likely due to aggregation of nanoparticles.
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Figure 2.16. Particle size of PLANA formulations before and after 72 h dialysis bag experiments.

Zeta potential measurements are summarized in Figure 2.17. For those formulations
incorporating the cationic lipid DOTAP, an increase in zeta potential after the 72 h dialysis
experiment was observed. This can be explained as the negatively-charged siRNA is released, the
positive charge of the cationic lipid is unmasked, resulting in a more positive surface charge.
Formulations without DOTAP did not display much change in zeta potential.
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Figure 2.17. Surface charge of PLANA formulations before and after 72 h dialysis bag
experiments.

2.3.9. Cytotoxicity
A critical factor in the success of a delivery system is its lack of cytotoxicity. Cell viability
following treatment of the different PLANA formulations was assessed using a CCK assay on the
MDA-MB-231 cell line. The cytotoxicity of the formulations was tested at four different
concentrations: 25, 50, 75, and 100 nM. Additionally, formulations with no siRNA were prepared,
and their toxicity were evaluated to ensure that toxicity is not due to the siRNA.
The results of LP-C18 PLANA and CP-C18 PLANA formulations are summarized in
Figures 2.18 and 2.19, respectively. Formulations LANA and PLANA A were found to be toxic
to the cells. Both of these formulations contain the cationic lipid DOTAP, giving a reason to
consider that toxicity is coming from DOTAP at the concentration used. On the contrary, LP-C18
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and CP-C18 PLANAs B, C, and D showed no significant cytotoxicity. The removal of DOTAP
led to much higher cell viability.
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Figure 2.18. Cytotoxicity profile of different LP-C18 PLANA formulations.
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Figure 2.19. Cytotoxicity profile of different CP-C18 PLANA formulations.
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NT

Low to no toxicity to normal cells is a crucial factor for a delivery system. Additional
toxicity assays were performed on a few different healthy human cell lines: MRC-5 lung cells,
H9C2 myocardium cells, Hepa RG Hepatocytes, and PSC epidermal keratinocytes (Figure 2.20).
LP-C18 and CP-C18 PLANA D were tested at 50 nM and 100 nM on each cell line. From this
analysis, no significant toxicity was found at any of the concentrations in any of the healthy human

in Healthy Human Cells

cell lines.
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Figure 2.20. PLANA D toxicity in healthy human cells.

2.3.10. Cellular uptake studies
2.3.10.1. Flow cytometry
Flow cytometry was performed on the MDA-MB-231 cell line to determine the cellular
internalization of several study groups: no treatment, AF488-siRNA only, AF488-siRNA and
peptide, AF488-siRNA, peptide, and DOPE, LANA, PLANA A, PLANA B, PLANA C, and
PLANA D. The experiments were run with either LP-C18 (Figure 2.21) or CP-C18 (Figure 2.22).
All treatment groups had a final siRNA concentration of 36 nM. The fluorescein isothiocyanate
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(FITC) channel was utilized for the quantification of cell-associated fluorescence. After analysis
of each sample, the percentage of cells with a fluorescence signal and the mean fluorescence of
the cell population were calculated using the calibration of the signal gated with no treatment cells
to obtain an autofluorescence of approximately 1% of the total population.
From the results summarized in Figure 2.21, LP-C18 PLANA formulations C and D had
the highest uptake (82.13% and 78.41%, respectively), followed by formulation B (55.98%).
PLANAs C and D had comparable cellular uptake to the positive control, Lipofectamine . These
formulations both have reduced cholesterol content, which was found to improve cellular
internalization. Cholesterol increases the rigidity of nanoparticles, which has shown to improve
uptake. However, overcompensation of cholesterol can have a reverse effect, decreasing uptake as
well as cell viability13. This explains the lower cellular uptake that was observed for LANA (no
peptide), and PLANAs A, and B.
A few other treatment groups were included for comparison to PLANAs. Previously, it was
reported that the incorporation of the neutral lipid DOPE improved uptake10. These findings were
consistent with the results found in this study. The peptide/DOPE complex showed higher uptake
than LANA, LP-C18 and CP-C18 PLANAs A as well as CP-C18 PLANA C. However, the
improved upon formulations, PLANAs C and D presented much higher cellular internalization
than the peptide/DOPE complexes.
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Figure 2.21. Flow cytometry cellular uptake of various treatment groups. From left to right:
no treatment, AF488-siRNA only, AF488-siRNA and peptide, AF488-siRNA, peptide, and
DOPE, LANA, LP-C18 PLANA A, LP-C18 PLANA B, LP-C18 PLANA C, LP-C18
PLANA D, and Lipofectamine.

Low uptake was observed for LANA and CP-C18 PLANA formulation A, those containing
DOTAP. Similar results were found with CP-C18 PLANAs (Figure 2.22). The same trend was
found, with LANA and PLANA A showing low uptake (34.5% and 18.7%, respectively), due to
the presence of cationic lipid DOTAP. PLANA B showed higher uptake with 51.5% of cells
exhibiting uptake. Again, similar to LP-C18 PLANAs C and D, CP-C18 PLANAs C and D showed
the most substantial uptake of the experimental groups (85.0% and 90.0%, respectively). PLANAs
C and D have proven comparable uptake to the commercially available Lipofectamine™, but
without the undesired cytotoxicity that the latter causes.
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Figure 2.22. Flow cytometry cellular uptake of various treatment groups. From left to
right: no treatment, AF488-siRNA only, AF488-siRNA and peptide, AF488-siRNA,
peptide, and DOPE, LANA, CP-C18 PLANA A, CP-C18 PLANA B, CP-C18 PLANA C,
CP-C18 PLANA D, and Lipofectamine.

2.3.10.2. Confocal Microscopy
Additional uptake studies using confocal microscopy were done to corroborate the results
obtained from flow cytometry. The MDA-MB-231 cell line was treated with one of the following
groups: AF488-siRNA only, Lipofectamine™, LP-C18 PLANA D, or CP-C18 PLANA D. Texas
Red Phalloidin solution was used to stain the cell membrane, and DAPI used to stain the nucleus.
A Nikon Ti E confocal microscope was used to image the cells. The results are displayed in Figure
2.23. The study group with siRNA only showed no uptake, a finding that was expected as siRNA
is unable to internalize into cells without a delivery system. siRNA internalization was observed
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for Lipofectamine™, LP-C18 PLANA D, and CP-C18 PLAN A D. These results are consistent
with the uptake results obtained from flow cytometry (Figures 2.21 and 2.22). Comparable cellular
uptake was observed for Lipofectamine™, LP-C18 PLANA D and CP-C18 PLANA D. From the
images, it appears that PLANAs are localized in the cytosol. There is no need for PLANAs to
reach

the

nucleus,

as

siRNA

targets

mRNA

in

the

cytoplasm.

DAPI (Nuclei)

AF488-siRNA

TR (Membrane)

Merged

DAPI (Nuclei)

AF488-siRNA

TR (Membrane)

Merged
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Lipofectamine

LP-C18
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Figure 2.23. Confocal microscopy of PLANA D along with the siRNA only and Lipofectamine™
controls.
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2.3.11. Silencing
Following cellular uptake studies, the best internalized PLANA formulations were selected
for protein silencing evaluation. CP-C18 PLANAs C and D were chosen for silencing in the MDAMB-231 cell line. For this study, the ribosomal protein S6 kinase alpha-5 RPS6KA5 (also known
as MSK1) and the proto-oncogene tyrosine-protein kinase Src were targeted for downregulation
in MDA-MB-231 triple-negative breast cancer cells.
The RPS6KA5 gene is involved in cell signaling and is overexpressed in breast cancer,
making it an ideal target for protein silencing. Western blot was performed with Lipofectamine
as a positive control and no treatment as the negative control. To normalize the intensity of the
bands of the targeted protein, the GAPDH endogenous gene was used. LP-C18 and CP-C18
PLANA D had comparable silencing to the commercially available Lipofectamine

(Figures 2.24

and 2.25), while, maintaining low cytotoxicity (Figures 2.18 and 2.19), a shortcoming known of
Lipofectamine . As shown in Figure 2.25, LP-C18 and CP-C18 PLANA D formulations
downregulated RPS6KA5 protein expression to 28% and 29%, respectively, compared to no
treatment, whereas Lipofectamine

only downregulated protein expression to 38%.
RPS6KA5 (MSK1)

GAPDH

Figure 2.24. Silencing of RPS6KA5 protein using western blot.
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Figure 2.25. RPS6KA5 protein expression.

The Src gene is involved in cell proliferation and is overexpressed in breast cancer. Again,
the GAPDH endogenous gene was used to normalize the intensity of the targeted protein. As
shown in Figure 2.26, both LP-C18 and CP-C18 PLANA D formulations led to significant Src
protein silencing. Compared to no treatment, cells treatment with LP-C18 and CP-C18 PLANA D
formulations exhibited 37% and 39% protein expression, respectively (Figure 2.27). Both LP-C18
and CP-C18 PLANA formulation D has proven to silence the Src protein in MDA-MB-231 breast
cancer cells as well as Lipofectamine , without the undesired cytotoxicity that the latter poses.
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Figure 2.26. Silencing of Src protein using western blot.
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Figure 2.27. Src protein expression.

2.4.

Conclusion
This project was conducted in order to study the hypothesis that fatty acyl peptide

conjugates incorporated into a multicomponent lipid nanoparticle would enhance cellular delivery
of siRNA and protein silencing in vitro. It was established that the designed PLANAs were able
to incorporate peptide into an appropriately sized multicomponent nanoparticle. The incorporation
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of siRNA into a PLANA multicomponent lipid nanoparticle allowed a more sustained release
profile of siRNA. The optimization of PLANAs led to the construction of PLANAs C and D,
which showed efficient cellular internalization of siRNA while maintaining low cytotoxicity in
healthy and triple-negative breast cancer cells. Both LP-C18 and CP-C18 PLANA D were able to
effectively downregulate both the RPS6KA5 and Src proteins in MDA-MB-231 cells, at
comparable rates to the commercially available Lipofectamine . The results from this study will
help further the development of siRNA delivery therapeutics.
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2.5. Future Directions
The incorporation of fatty acyl peptide conjugates into a multicomponent lipid nanoparticle
to form PLANAs was found to effectively deliver siRNA to breast cancer cells. Formulations
without the cationic lipid DOTAP and with lower cholesterol content (PLANAs C and D) resulted
in the highest cellular uptake, and PLANA D was chosen for silencing studies. The RPS6KA5 and
Src proteins were effectively silenced via delivery by both LP-C18 and CP-C18 PLANA D. Future
work includes CD analysis for characterization of the secondary structures formed by the
PLANAs, silencing of further overexpressed proteins in breast cancer such as the MCL1 protein,
as well as in vivo studies using a mouse model.
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Chapter 3
Delivery of CRISPR/Cas9 For the Transfection of Breast Cancer Cells Using PLANAs

Abstract
CRISPR/Cas9 is an emerging gene therapy tool that has grown a great deal of attention in
the last few years. Though the gene-editing technique has exhibited great potential in a variety of
diseases, one of the biggest challenges is the delivery of the CRISPR/Cas9 plasmid to targeted
cells. One of the methods of delivery of CRISPR/Cas9 that has been studied is lipid nanoparticles.
In this study, we utilized a multicomponent lipid nanoparticle that incorporated a fatty acyl
conjugated cell-penetrating peptide called as peptide lipid-associated nucleic acids (PLANAs).
Optimized PLANA formulations were used for delivery of CRISPR/Cas9 with gRNA targeting
the RPS6KA5 to MDA-MB-231 triple-negative breast cancer cells. The results from this study
indicated that CP-C18 PLANAs B, C, and D allow effective transfection. CP-C18 PLANAs B, C,
and D displayed 47.1%, 38.1%, and 49.0% transfection efficiencies, respectively. Compared to the
commercially available transfection agent Lipofectamine™, which displayed a 22.3% transfection
efficiency, all three CP-C18 PLANA formulations tested proved to improve cellular delivery of
CRISPR/Cas9 and in turn enhance the gene editing efficiency.
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3.1. Introduction
3.1.1. Background
The CRISPR/Cas9 method of gene therapy has become attractive to researchers. However,
for this method to be effective at targeted gene editing, the challenge of cellular delivery must be
overcome. Numerous methods of delivery have been studied in attempt to overcome this barrier.
A variety of physical delivery techniques have been investigated. For example, electroporation, a
traditional method that utilizes an electric field to temporarily create pores in the cell membrane
has been shown to allow delivery of CRISPR/Cas91. Similarly, microinjection, which works by
puncturing the cell membrane to directly delivery protein or DNA to the cell, has been employed
for CRISPR/Cas9 delivery2. Though, this method is limited in its necessity for individual cell
manipulation3. Another physical method of delivery is hydrodynamic injection. This method
involves the direct injection of solution using high volume and pressure and has been used in tail
vein mouse models for delivery of CRISPR/Cas94. Another category of non-viral CRISPR/Cas9
delivery systems are polymer nanoparticles. Predominantly used in this category are cationic
polymers, for example, poly(ethyleneimine) (PEI) and poly(amido amine) (PAMAM), both of
which utilize a positively-charged polymer to enhance interactions with negatively-charged gRNA
and thus improve cellular delivery5, 6. An additional nanoparticle delivery method utilizes lipids.
Again, cationic lipids are favored, due to improved interactions with gRNA. pH sensitive amino
lipids have been found to increase gene editing efficiency of CRISPR/Cas9 7 and ionizable lipids
were found to deliver Cas9 protein and subsequently modifying 80% of the targeted genome
modification8. Further CRISPR/Cas9 delivery method studies include induced transduction by
osmocytosis and propane betaine (iTOP)9, mechanical cell deformation10, DNA nanostructures11,
AuNPs12, and CPPs13.
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In this study, the optimized PLANA formulations described in Chapter 2 were utilized for
CRISPR/Cas9 delivery. The objective was to enhance CRISPR/Cas9 cellular delivery in order to
improve transfection efficiency of targeted genes. Here, we targeted the RPS6KA5 gene for
knockdown, in order to disrupt the overexpression of the RPS6KA5 protein in breast cancer cells.
3.1.2. Hypothesis
In this section of the study, we hypothesized that using PLANAs for cellular delivery of
CRISPR/Cas9 will enhance the transfection efficiency of MDA-MB-231 triple negative breast
cancer cells, leading to the improved gene editing of the targeted RPS6KA5 gene.

3.2. Experimental procedures
3.2.1. Materials
H-Arg(Pbf)-2-chlorotrityl resin (0.44 mmol/g), Fmoc-Arg(Pbf)-OH, Fmoc-Lys(Dde)-OH,
were provided by AAPPTec (Louisville, KY, USA). Palmitic acid, stearic acid, piperdine, N,Ndiisopropylethylamine (DIPEA), hydrazine monohydrate, anisole, thioanisole, dithiothreiitol
(DTT), N-methylmorpholine, trifluoroacetic acid, acetonitrile, dichloromethane, α-cyano-4hydroxycinnamic acid, and trifluoroethanol (TFE) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). SYBR Green II, LipofectamineTM 2000 was obtained from Life Technologies (Grand
Island, NY, USA). 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-3trimethylammonium-propane (DOTAP; chloride salt), cholesterol, phosphatidyl choline, and
Avanti Mini Extruder were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Sense
(5′-TTGATTTCATCTGCATCACGGTTTT-3′)

and

antisense

(5′-

CGTGATGCAGATGAAATCAACGGTG-3′) oligonucleotides targeting the RPS6KA5 gene and
T7 endonuclease Alt-R Genome Editing Detection Kit were purchased from Integrated DNA

99

Technologies. GeneArt CRISPR Nuclease CD4 enrichment Kit (Catalogue number A21175), One
Shot TOP10 competent E. coli cells (Catalogue number C4040-03), and S.O.C. medium
(Catalogue number 15544-034) were purchased from Life Technologies (Carlsbad, CA). Plasmids
were purified using the Plasmid Miniprep Classic kit (Catalogue number D4015S). LB broth
(Catalogue number C6321) was purchased from Hardy Diagnostics, LB agar (Catalogue number
BP1425-500) and Ampicillin (Catalogue number 69-52-3) were purchased from Fisher Scientific.
BSA (Catalogue number 9048-46-8) was purchased from BioWorld, and EDTA (Catalogue
number BDH9232-500G) was purchased from VWR. MojoSort Human CD4 nanobeads
(Catalogue number 480013) and Mojo magnet (Catalogue number 480019) were purchased from
BioLegend. The concentration of the purified plasmids was determined using Nanodrop
(ThermoScientific, NanoDrop OneC).

3.2.2. Methods
3.2.2.1. Cell Line
Human breast cancer cell line MDA-MB-231 was purchased from American Type Culture
Collection (ATCC; Manassas, VA; Cat. #: HTB-26™). The cell line was cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% (v/v) FBS, 100 µg/mL streptomycin, and
100U/mL penicillin. The cells were maintained at 37 °C and 5% CO 2 and subcultured when 8090% confluent. Cells were discarded after 30 subcultures, and a new batch of cells was thawed
and cultured according to the same protocol.
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3.2.2.2. Design guide RNA
Integrated DNA Technologies CRISPR design software was utilized to design guide RNA
(sense and antisense oligonucleotides) to target the RPS6KA5 gene.

3.2.2.3. Anneal top and bottom guide RNA to get double-stranded gRNA
Equal amounts of the sense and antisense guide RNA oligonucleotides were annealed to
generate a double stranded oligonucleotide. 5 µL of 200 uM Forward and Reverse single-stranded
oligonucleotides, 2 µL of 10X Oligonucleotide Annealing Buffer (Life Technologies, Cat. No.
A21174), and 8 µL DNase/RNase-Free Water were added to a clean microcentrifuge tube. The
mixture was briefly centrifuged and 5 µL was then transferred to a clean microcentrifuge tube. The
tube was incubated at 95 ºC for 4 min. in a heat block. The tube was removed and allowed to cool
to 25 ºC for 10 min. The tube was briefly centrifuged and mixed gently. A 5 nM working
concentration was prepared by diluting the 50 µM solution using DNase/RNase-Free water.

3.2.2.4. Ligate the double-stranded guide RNA to the GeneArt CRISPR Nuclease Vector
4 µL 5X ligation buffer (Life Technologies, Cat. No. A21174), 2 µL Linearized GeneArt
CRISPR Nuclease Vector (Life Technologies, Cat. No. A21174), and 1 µL T4 DNA Ligase (Life
Technologies, Cat. No. 15224-017) were added to a clean microcentrifuge tube. 3.5 µL of this
mixture, 2 µL of the double-stranded oligonucleotide, and 4.5 µL of DNase/RNase-Free water
were added to a second clean microcentrifuge tube. The tube was incubated overnight at 25 C.
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3.2.2.5. Transformation of Competent E. Coli Cells
LB broth was prepared by dissolving 15 g broth base (Hardy Diagnostics, Cat. No. C6321)
in 1L deionized water and the pH adjusted to 7.4. The broth was autoclaved for 20 min. and cooled
to room temperature. 1 mL ampicillin (Fisher Scientific, Cat. No. 69-52-3) was added to the LB
broth. LB agar plates were prepared by adding 40 g LB agar (Fisher BioReagents, Cat. No.
BP1425-500) to 1 L deionized water and autoclaved for 20 min. then cooled to room temperature.
1 mL of ampicillin was added to the LB agar. 35 mL was added to a 9 cm plate and allowed to
harden. Once hardened, 45 µL ampicillin was added and spread evenly. Plates were stored at 4 ºC.
One Shot TOP10 chemically competent E. coli cells (Life Technologies, Cat. No. C404003) were thawed on ice. 3 µL of the ligation reaction was added to a vial of the One Shot TOP10
chemically competent E. coli and mixed gently by swirling the tube. The tube was immediately
placed on ice for 30 min. then heat shocked at 42 ºC for 30 seconds. The tubes were immediately
transferred to ice, and 250 µL S.O.C. medium (Life Technologies, Cat. No. 15544-034) was added.
The tube was then shaken horizontally (200 rpm) at 37 ºC for 1 h. The mixture was then plated on
3 prepared agar plates and incubated overnight at 37 ºC. Volumes of 40 µL, 80 µL, and 120 µL
were added to ensure that at least one plate had well-spaced colonies.
The E. coli colonies were picked and propagated in ampicillin containing LB media. The
LB media was centrifuged to get bacterial pellets which were using for plasmid isolation as
described below:

3.2.2.6. Plasmid purification
Plasmids were purified using the Zymo Research ZR Plasmid Miniprep Classic kit (Cat.
No D4015S). 3 mL LB broth was added to a 5 mL culture tube. A single isolated colony was added
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to the culture tube. This was repeated for 3 more isolated colonies. The tubes were shaken
horizontally (200 rpm) at 37 ºC overnight. Once turbid, the cells were centrifuged in a 1.5 mL tube
at 8,000 g for 5 min. The supernatant was discarded. 200 µL of P1 Buffer (Zymo Research, Cat
No. D4027-1-S) was added to the tube, and the pellet was resuspended by pipetting up and down.
200 µL of P2 Buffer (Zymo Research, Cat. No. D4027-2-S) was added and mixed by inverting the
tube 2-4 times and incubated at room temperature for 1-2 min. 400 µL of P3 Buffer (Zymo
Research, Cat. No. D4027-3-S) was added and mixed gently and incubated at room temperature
for 1-2 minutes. The mixture was then centrifuged for 4 min. at 11,000 g. A Zymo-Spin IIN column
(Zymo Research, Cat. No. C1019-50) was placed in a collection tube, and the supernatant was
added to the Zymo-Spin IIN column. The Zymo-Spin IIN assembly was then centrifuged for 1 min
at 11,000 g. The flow through was then discarded, and the column was returned to the same
collection tube. 200 µL Endo-Wash Buffer (Zymo Research, Cat. No. D4036-3-S) was added to
the column and centrifuged for 30 seconds at 11,000 g. 400 µL Plasmid Wash Buffer (Zymo
Research, Cat. No. D4027-4-S) was added to the column and centrifuged for 1 min. at 11,000 g
and repeated once more. The column was transferred to a clean 1.5 mL microcentrifuge tube and
50 µL of DNA Elution Buffer (Zymo Research, Cat. No. D3004-4-1) was added to the column
and incubated for 1 min. at room temperature. This was centrifuged for 1 min. at 11,000 g to elute
the purified plasmid.
The concentration of the purified plasmids was determined using Nanodrop
(ThermoScientific, NanoDrop OneC) and the plasmids were sent out to Retrogen for sequencing.
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3.2.2.7. Transfection of MDA-MB-231 cells
6-well plates were seeded with WT MDA 231 cells and allowed to reach 80% confluency.
For the positive control group, in 2 wells, the DMEM media (HyClone, Cat. No. SH30021.01) was
removed, and optimem media (Corning, Cat. No. 40-300-CV) added 6 hours before treatment. 2.5
µg of the purified plasmid was mixed with 2.5 µg Lipofectamine (Life Technologies, Cat. No.
11668-027) (positive control), and the mixture was added to one of the wells. This was repeated
using CP-C18 PLANAs B, C, and D in place of Lipofectamine. The cells were incubated at 37 ºC
for 6 h. After 6 h the media was removed and DMEM media added. The cells were then incubated
for 48 h at 37 ºC.

3.2.2.8. Cell Sorting
Mojo Buffer was prepared by mixing 50 mL 1X PBS (VWR, Cat. No. E703-1L), 250 mg
BSA (BioWorld, Cat. No. 9048-46-8), and 200 µL of 500 mM EDTA (VWR, Cat. No. BDH9232500G). Transfected cells were trypsinized for 2 min at 37 ºC then neutralized using DMEM media.
The cells were then centrifuged to pellet at 600 rpm for 5 min. The cells were then resuspended in
5 mL of Mojo Buffer. The cells were then filtered through a 30 µM cell strainer (MACS, Cat. No.
130-098-458). The cells were then centrifuged to pellet at 600 rpm for 5 min. The cells were
resuspended in 50 µL of Mojo Buffer. MojoSort Human CD4 Nanobeads (BioLegend, Cat. No.
480013) were vortexed for 5 touches at full speed. 5 µL of beads were added to the cells and
incubated on ice for 15 min. 2 mL of Mojo Buffer was added to the cells and placed in the Mojo
magnet (BioLegend, Cat. No. 480019) for 5 min. The non-transfected cells were then collected in
a clean tube. 1 mL of DMEM media was added to the tube in the magnet and swirled. The tube
was removed from the magnet, and the transfected cells added to another clean tube. 3 mL of Mojo

104

Buffer was added to the tube in the magnet, and the process repeated twice. The transfected cells
were then centrifuged to pellet, resuspended in 1 mL media, and seeded in a 24-well plate.
The success of CRISPR editing was confirmed using the T7 endonuclease Alt-R Genome
Editing Detection Kit.

3.3. Results and Discussion
3.3.1. Design guide RNA
The delivery of CRISPR/Cas9 via PLANAs was began with the decision on what gene to
target in MDA-MB-231 triple-negative breast cancer cells. The RPS6KA5 gene is known to be
overexpressed in breast cancer and was chosen as a target for gene therapy via CRISPR/Cas9.
Guide RNA (gRNA) was designed based on the predesigned Alt-R CRISPR-Cas9 guide RNA.
The predesigned gRNA with the lowest off-target score and the highest on-target score was chosen.

3.3.2. Annealing of gRNA and ligation to the GeneArt® CRISPR Nuclease CD4 Enrichment
Vector
The forward and reverse single-stranded gRNA were annealed and ligated into the
GeneArt® CRISPR Nuclease CD4 Enrichment Vector. The ligation reaction was first attempted
at room temperature overnight. The uncontrolled temperature led to unsuccessful ligation.
However, the reaction was attempted again at 25 °C overnight, and a successful ligation was
established.
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3.3.3. Transformation of competent E. coli Cells
Competent E. coli cells were transformed with the ligated CRISPR/Cas9 plasmid via heat
shock at 42 °C for 30 seconds. Once turbid, the transformed E. coli cells were plated on three
different prepared agar plates at three different volumes (40 µL, 80 µL, and 120 µL) to ensure
well-spaced colonies. The plates were incubated at 37 °C for 24 h. Some satellite colonies were
located on the plate loaded with 120 µL of transformed E. coli cells. In order to avoid picking up
satellite colonies, colonies were chosen from the 40 uL and 80 uL plates for propagation.

3.3.4. Plasmid purification
The Zymo Research ZR Plasmid Miniprep Classic kit was utilized for plasmid purification.
Once purified, the concentration of the plasmids was determined using Nanodrop. Samples were
sent to Retrogen for sequencing. Sequencing confirmed that the plasmids were successfully ligated
with the designed gRNA.

3.3.5. Transfection of MDA-MB-231 cells
The MDA-MB-231 triple-negative breast cancer cell line was chosen to study
CRISPR/Cas9 transfection efficiency via PLANAs. Cells were treated for 48 h at 37 °C with either
the positive control, Lipofectamine™, or CP-C18 PLANA B, C, or D. Following transfection, the
proficiency of transfection was analyzed. In order to determine the transfection efficiency of each
treatment group, cell sorting via magnetic beads was employed. MojoSort Human CD4 Nanobeads
will bind to the CD4 enriched CRISPR/Cas9 plasmid. When the cells and magnetic beads are
inserted into the Mojo magnet, the transfected cells with the CD4 enriched CRISPR/Cas9 vector
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will be attached to the magnetic beads will stick to the walls of the tube. The non-transfected cells
can then be discarded, leaving just the transfected cells.
Using this system, we were able to count the cells that were transfected to conclude the
percent transfection for each treatment group (Figure 3.2). All three CP-C18 PLANA formulations
that were tested (PLANA B, C, and D) were more efficient in delivering CRISPR/Cas9 to MDAMB-231 cells than Lipofectamine™. Lipofectamine™ was able to transfect 22.34% of cells,
whereas CP-C18 PLANA B, C, and D were able to transfect 47.06%, 38.13%, and 49.00% of cells,
respectively (Figure 3.2). Unlike in siRNA delivery, PLANA B showed comparable transfection
to PLANA D and even showed slightly better transfection efficiency than PLANA C. The higher
amount of cholesterol in PLANA B did not hinder cellular uptake of the CRISPR/Cas9 plasmid.
The CRISPR/Cas9 plasmid is significantly larger than siRNA (approximately 10,000 base pairs
and 20 base pairs, respectively), which seems to have influenced a distinctive nanoparticle
formation. The nanoparticle formation of PLANA B, containing a higher amount of cholesterol
with CRISPR/Cas9 was able to transfect MDA-MB-231 cells at equivalent levels to PLANA D,
and slightly higher levels to PLANA C.
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Figure 3.1. CRISPR/Cas9 transfection efficiency in MDA-MB-231 triple-negative breast cancer
cells. Commercially available Lipofectamine

was used as a positive control, and three treatment

groups (CP-C18 PLANAs B, C, and D) were tested. All three treatment groups had a higher
transfection rate than Lipofectamine .

3.4. Conclusion
This study has shown that CP-C18 PLANAs are more efficient at delivering CRISPR/Cas9
to MDA-MB-231 cells than commercially available Lipofectamine . Lipofectamine was found to
have a 22.3% transfection efficiency, whereas CP-C18 PLANAs B, C, and D displayed
transfection efficiencies of 47.1%, 38.1%, and 49.0%, respectively. Moreover, it was found that
the high cholesterol content did not hinder the ability of the PLANA formulation from delivering
CRISPR/Cas9 for gene editing. The success of PLANAs as a delivery agent for CRISPR/Cas9 is
a step further in the optimization of applicable CRISPR/Cas9 gene therapy.
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3.5. Future Directions
PLANAs have shown efficacy in the CRISPR/Cas9 transfection of MDA-MB-231 cells.
The multicomponent lipid nanoparticles not only surpass Lipofectamine’s transfection ability, but
also maintain low cytotoxicity. Future work in this area can be done to further confirm transfection
efficiencies using PCR, target additional genes for silencing, and transfect other cell lines to assess
the breadth of CRISPR/Cas9 delivery via PLANAs.
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